https://trial.medpath.com/news/blood-volume-analysis-outperforms-traditional-methods-in-heart-failure-assessment-multicenter-study-shows 2025-02-13T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-volume-analysis-outperforms-traditional-methods-in-heart-failure-assessment-multicenter-study-shows 2025-02-13T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-biosciences-reports-strong-pipeline-progress-and-1-1b-cash-position-for-2024 2025-02-13T13:31:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ideaya-biosciences-reports-strong-pipeline-progress-and-1-1b-cash-position-for-2024 2025-02-13T13:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/new-analysis-shows-next-gen-alzheimer-s-drugs-add-8-10-months-of-independent-living 2025-02-13T13:31:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-analysis-shows-next-gen-alzheimer-s-drugs-add-8-10-months-of-independent-living 2025-02-13T13:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/novel-lion-trial-combines-anti-inflammatory-drug-with-immunotherapy-to-combat-advanced-cancers 2025-02-13T13:31:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-lion-trial-combines-anti-inflammatory-drug-with-immunotherapy-to-combat-advanced-cancers 2025-02-13T13:31:11+00:00 hourly 0.9 https://trial.medpath.com/news/deepmind-alphafold-veteran-raises-50m-to-launch-ai-powered-protein-design-platform 2025-02-13T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deepmind-alphafold-veteran-raises-50m-to-launch-ai-powered-protein-design-platform 2025-02-13T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-and-amgen-discontinue-ide397-amg-193-combination-study-despite-promising-preclinical-data 2025-02-13T12:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ideaya-and-amgen-discontinue-ide397-amg-193-combination-study-despite-promising-preclinical-data 2025-02-13T12:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-launches-generic-clindamycin-phosphate-foam-for-dermatological-treatment 2025-02-13T12:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-launches-generic-clindamycin-phosphate-foam-for-dermatological-treatment 2025-02-13T12:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/cost-and-implementation-barriers-challenge-adoption-of-novel-muc-therapies-asco-gu-studies-show 2025-02-13T11:42:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cost-and-implementation-barriers-challenge-adoption-of-novel-muc-therapies-asco-gu-studies-show 2025-02-13T11:42:27+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-advances-pipeline-with-multiple-regulatory-wins-and-strategic-partnerships-in-2024 2025-02-13T11:01:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-advances-pipeline-with-multiple-regulatory-wins-and-strategic-partnerships-in-2024 2025-02-13T11:01:10+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-and-ai-drive-major-advances-in-cancer-treatment-outcomes 2025-02-13T10:45:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-medicine-and-ai-drive-major-advances-in-cancer-treatment-outcomes 2025-02-13T10:45:33+00:00 hourly 0.9 https://trial.medpath.com/news/torrent-capital-secures-8-75m-financing-to-expand-cryptocurrency-investment-portfolio 2025-02-13T10:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/torrent-capital-secures-8-75m-financing-to-expand-cryptocurrency-investment-portfolio 2025-02-13T10:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-biontech-launches-landmark-phase-3-trial-for-mrna-based-influenza-vaccine 2025-02-13T10:32:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-biontech-launches-landmark-phase-3-trial-for-mrna-based-influenza-vaccine 2025-02-13T10:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-in-groundbreaking-optogenetic-gene-therapy-trial-for-retinitis-pigmentosa 2025-02-13T10:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-dosed-in-groundbreaking-optogenetic-gene-therapy-trial-for-retinitis-pigmentosa 2025-02-13T10:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/bioarctic-signs-1-35-billion-deal-with-bms-reports-growing-leqembi-sales-in-q4-2024 2025-02-13T10:32:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioarctic-signs-1-35-billion-deal-with-bms-reports-growing-leqembi-sales-in-q4-2024 2025-02-13T10:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-and-j-j-halt-phase-3-trial-of-e-coli-vaccine-due-to-insufficient-efficacy 2025-02-13T10:31:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-and-j-j-halt-phase-3-trial-of-e-coli-vaccine-due-to-insufficient-efficacy 2025-02-13T10:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-hope-trial-tests-novel-light-sound-therapy-device-for-moderate-alzheimer-s-treatment 2025-02-13T10:31:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-hope-trial-tests-novel-light-sound-therapy-device-for-moderate-alzheimer-s-treatment 2025-02-13T10:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/scotiabank-raises-travere-therapeutics-price-target-following-planned-filspari-snda-filing 2025-02-13T10:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scotiabank-raises-travere-therapeutics-price-target-following-planned-filspari-snda-filing 2025-02-13T10:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/odiot-holding-secures-eur2-16m-capital-raise-to-expand-luxury-silversmith-operations 2025-02-13T08:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/odiot-holding-secures-eur2-16m-capital-raise-to-expand-luxury-silversmith-operations 2025-02-13T08:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/cognito-therapeutics-expands-leadership-team-with-four-key-executive-appointments-ahead-of-alzheimer-s-treatment-launch 2025-02-13T08:31:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cognito-therapeutics-expands-leadership-team-with-four-key-executive-appointments-ahead-of-alzheimer-s-treatment-launch 2025-02-13T08:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/novel-cdk2-inhibitor-inx-315-shows-promise-in-overcoming-cancer-drug-resistance-study-reveals 2025-02-13T08:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-cdk2-inhibitor-inx-315-shows-promise-in-overcoming-cancer-drug-resistance-study-reveals 2025-02-13T08:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/nih-funding-cuts-under-trump-administration-threaten-early-stage-biopharma-innovation 2025-02-13T07:44:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-funding-cuts-under-trump-administration-threaten-early-stage-biopharma-innovation 2025-02-13T07:44:28+00:00 hourly 0.9 https://trial.medpath.com/news/novel-briovad-heart-pump-begins-clinical-trial-at-university-of-michigan-challenging-heartmate-3-s-market-dominance 2025-02-13T07:31:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-briovad-heart-pump-begins-clinical-trial-at-university-of-michigan-challenging-heartmate-3-s-market-dominance 2025-02-13T07:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/pipeline-for-pulmonary-arterial-hypertension-treatment-expands-with-55-companies-developing-novel-therapies 2025-02-13T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pipeline-for-pulmonary-arterial-hypertension-treatment-expands-with-55-companies-developing-novel-therapies 2025-02-13T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/groundbreaking-uk-study-advances-treatment-monitoring-for-pediatric-traumatic-brain-injuries 2025-02-13T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/groundbreaking-uk-study-advances-treatment-monitoring-for-pediatric-traumatic-brain-injuries 2025-02-13T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/black-women-significantly-underrepresented-in-triple-negative-breast-cancer-clinical-trials-despite-higher-disease-burden 2025-02-13T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/black-women-significantly-underrepresented-in-triple-negative-breast-cancer-clinical-trials-despite-higher-disease-burden 2025-02-13T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/watchman-device-shows-promise-for-afib-patients-seeking-alternatives-to-blood-thinners 2025-02-13T05:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/watchman-device-shows-promise-for-afib-patients-seeking-alternatives-to-blood-thinners 2025-02-13T05:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/esketamine-shows-promise-in-small-pilot-trial-for-rett-syndrome-symptoms 2025-02-13T04:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esketamine-shows-promise-in-small-pilot-trial-for-rett-syndrome-symptoms 2025-02-13T04:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/survaxm-glioblastoma-trial-advances-following-positive-interim-analysis 2025-02-13T04:31:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/survaxm-glioblastoma-trial-advances-following-positive-interim-analysis 2025-02-13T04:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/selkirk-pharma-launches-clinfast-service-to-accelerate-clinical-trial-material-production 2025-02-13T03:04:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/selkirk-pharma-launches-clinfast-service-to-accelerate-clinical-trial-material-production 2025-02-13T03:04:53+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-shows-promising-results-for-novel-encapsulated-cell-therapy-in-mactel-treatment 2025-02-13T02:31:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-shows-promising-results-for-novel-encapsulated-cell-therapy-in-mactel-treatment 2025-02-13T02:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-technologies-and-modular-design-revolutionize-pharmaceutical-facility-construction 2025-02-13T02:02:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-technologies-and-modular-design-revolutionize-pharmaceutical-facility-construction 2025-02-13T02:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-voranigo-first-targeted-therapy-for-idh-mutant-glioma-brain-cancer 2025-02-13T01:31:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-voranigo-first-targeted-therapy-for-idh-mutant-glioma-brain-cancer 2025-02-13T01:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/evolving-cervical-cancer-treatment-landscape-surgical-approaches-and-immunotherapy-sequencing-take-center-stage 2025-02-13T01:31:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evolving-cervical-cancer-treatment-landscape-surgical-approaches-and-immunotherapy-sequencing-take-center-stage 2025-02-13T01:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/novel-magshapetm-microcapsules-show-superior-magnesium-absorption-in-clinical-trial 2025-02-13T01:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-magshapetm-microcapsules-show-superior-magnesium-absorption-in-clinical-trial 2025-02-13T01:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/japan-approves-groundbreaking-viral-therapy-teserpaturev-for-glioblastoma-treatment 2025-02-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-approves-groundbreaking-viral-therapy-teserpaturev-for-glioblastoma-treatment 2025-02-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-radioligand-therapy-shows-complete-response-in-muscle-invasive-bladder-cancer-patient 2025-02-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-radioligand-therapy-shows-complete-response-in-muscle-invasive-bladder-cancer-patient 2025-02-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/minimalist-dna-hydrogel-shows-promise-for-sustained-drug-delivery-with-improved-retention 2025-02-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minimalist-dna-hydrogel-shows-promise-for-sustained-drug-delivery-with-improved-retention 2025-02-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/neumora-therapeutics-announces-major-leadership-restructuring-as-paul-berns-takes-ceo-role 2025-02-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neumora-therapeutics-announces-major-leadership-restructuring-as-paul-berns-takes-ceo-role 2025-02-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/apple-launches-landmark-5-year-health-study-to-explore-technology-s-impact-on-wellbeing 2025-02-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apple-launches-landmark-5-year-health-study-to-explore-technology-s-impact-on-wellbeing 2025-02-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/manchester-s-pill-connect-secures-investment-to-revolutionize-clinical-trial-drug-adherence-tracking 2025-02-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/manchester-s-pill-connect-secures-investment-to-revolutionize-clinical-trial-drug-adherence-tracking 2025-02-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/galapagos-reports-strong-clinical-results-for-cell-therapy-program-plans-strategic-split-into-two-companies 2025-02-12T22:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galapagos-reports-strong-clinical-results-for-cell-therapy-program-plans-strategic-split-into-two-companies 2025-02-12T22:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/novel-gene-silencing-therapy-shows-promise-for-long-term-cholesterol-control-with-single-dose 2025-02-12T22:32:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-gene-silencing-therapy-shows-promise-for-long-term-cholesterol-control-with-single-dose 2025-02-12T22:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-s-sohonos-becomes-first-approved-treatment-for-fop-in-canada 2025-02-12T22:31:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-s-sohonos-becomes-first-approved-treatment-for-fop-in-canada 2025-02-12T22:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-ease-trial-shows-promise-birch-triterpenes-demonstrates-sustained-wound-reduction-in-epidermolysis-bullosa-patients 2025-02-12T22:31:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-ease-trial-shows-promise-birch-triterpenes-demonstrates-sustained-wound-reduction-in-epidermolysis-bullosa-patients 2025-02-12T22:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/anaptysbio-s-phase-2b-rheumatoid-arthritis-trial-results-face-scrutiny-over-placebo-handling 2025-02-12T20:01:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anaptysbio-s-phase-2b-rheumatoid-arthritis-trial-results-face-scrutiny-over-placebo-handling 2025-02-12T20:01:23+00:00 hourly 0.9 https://trial.medpath.com/news/novel-car-t-trial-aims-to-prevent-recurrence-in-aggressive-b-cell-lymphoma-patients 2025-02-12T19:33:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-car-t-trial-aims-to-prevent-recurrence-in-aggressive-b-cell-lymphoma-patients 2025-02-12T19:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/maxona-s-novel-non-opioid-pain-therapy-max-001-successfully-completes-phase-1-trials 2025-02-12T19:32:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maxona-s-novel-non-opioid-pain-therapy-max-001-successfully-completes-phase-1-trials 2025-02-12T19:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/abcuro-secures-200m-series-c-funding-to-advance-novel-ibm-treatment-ulviprubart 2025-02-12T19:32:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abcuro-secures-200m-series-c-funding-to-advance-novel-ibm-treatment-ulviprubart 2025-02-12T19:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-adcetris-approval-for-relapsed-large-b-cell-lymphoma-treatment 2025-02-12T19:32:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-adcetris-approval-for-relapsed-large-b-cell-lymphoma-treatment 2025-02-12T19:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/dana-farber-researchers-to-present-groundbreaking-cellular-therapy-studies-at-2025-tandem-meetings 2025-02-12T19:31:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dana-farber-researchers-to-present-groundbreaking-cellular-therapy-studies-at-2025-tandem-meetings 2025-02-12T19:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-to-evaluate-dexamethasone-implant-with-vitrectomy-for-proliferative-diabetic-retinopathy 2025-02-12T19:31:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-to-evaluate-dexamethasone-implant-with-vitrectomy-for-proliferative-diabetic-retinopathy 2025-02-12T19:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-partners-with-synthon-for-novel-cancer-drug-development-in-1-5-billion-us-market 2025-02-12T18:24:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-lifesciences-partners-with-synthon-for-novel-cancer-drug-development-in-1-5-billion-us-market 2025-02-12T18:24:03+00:00 hourly 0.9 https://trial.medpath.com/news/novel-approach-converting-parallel-cluster-trials-to-stepped-wedge-design-shows-promise-in-global-health-research 2025-02-12T18:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-approach-converting-parallel-cluster-trials-to-stepped-wedge-design-shows-promise-in-global-health-research 2025-02-12T18:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-faces-critical-q4-earnings-report-amid-leqembi-challenges-and-strategic-developments 2025-02-12T17:33:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-faces-critical-q4-earnings-report-amid-leqembi-challenges-and-strategic-developments 2025-02-12T17:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/seaport-therapeutics-secures-225m-series-b-to-advance-novel-neuropsychiatric-drug-pipeline 2025-02-12T17:32:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seaport-therapeutics-secures-225m-series-b-to-advance-novel-neuropsychiatric-drug-pipeline 2025-02-12T17:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/experts-explore-hierarchical-composite-endpoints-to-transform-nephrology-clinical-trials 2025-02-12T17:01:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experts-explore-hierarchical-composite-endpoints-to-transform-nephrology-clinical-trials 2025-02-12T17:01:12+00:00 hourly 0.9 https://trial.medpath.com/news/tivic-health-acquires-late-stage-radiation-treatment-entolimod-expanding-into-immunotherapy 2025-02-12T16:36:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tivic-health-acquires-late-stage-radiation-treatment-entolimod-expanding-into-immunotherapy 2025-02-12T16:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-secures-250m-from-royalty-pharma-to-advance-lupus-antibody-into-phase-iii-trials 2025-02-12T16:36:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-secures-250m-from-royalty-pharma-to-advance-lupus-antibody-into-phase-iii-trials 2025-02-12T16:36:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-status-to-oncusp-s-novel-antibody-drug-conjugate-for-platinum-resistant-ovarian-cancer 2025-02-12T16:35:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-status-to-oncusp-s-novel-antibody-drug-conjugate-for-platinum-resistant-ovarian-cancer 2025-02-12T16:35:55+00:00 hourly 0.9 https://trial.medpath.com/news/nih-funded-research-drives-breakthrough-in-cystic-fibrosis-treatment-with-trikafta 2025-02-12T16:35:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-funded-research-drives-breakthrough-in-cystic-fibrosis-treatment-with-trikafta 2025-02-12T16:35:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-status-to-nkgen-s-nk-cell-therapy-troculeucel-for-moderate-alzheimer-s-disease 2025-02-12T16:35:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-status-to-nkgen-s-nk-cell-therapy-troculeucel-for-moderate-alzheimer-s-disease 2025-02-12T16:35:18+00:00 hourly 0.9 https://trial.medpath.com/news/zolgensma-s-journey-from-2m-charity-funded-research-to-world-s-most-expensive-drug 2025-02-12T16:34:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zolgensma-s-journey-from-2m-charity-funded-research-to-world-s-most-expensive-drug 2025-02-12T16:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/uva-initiates-clinical-trial-of-ai-enhanced-automated-insulin-delivery-system-for-type-1-diabetes 2025-02-12T16:34:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uva-initiates-clinical-trial-of-ai-enhanced-automated-insulin-delivery-system-for-type-1-diabetes 2025-02-12T16:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/irlab-reports-strong-progress-in-parkinson-s-drug-development-pipeline-with-multiple-clinical-milestones 2025-02-12T14:31:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/irlab-reports-strong-progress-in-parkinson-s-drug-development-pipeline-with-multiple-clinical-milestones 2025-02-12T14:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/rosnilimab-shows-breakthrough-results-in-phase-2b-rheumatoid-arthritis-trial-with-record-setting-disease-control 2025-02-12T14:01:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rosnilimab-shows-breakthrough-results-in-phase-2b-rheumatoid-arthritis-trial-with-record-setting-disease-control 2025-02-12T14:01:24+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-therapeutics-casgevy-launch-shows-steady-progress-amid-cautious-market-outlook 2025-02-12T13:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-therapeutics-casgevy-launch-shows-steady-progress-amid-cautious-market-outlook 2025-02-12T13:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-advances-to-phase-ii-trial-of-inkmunetm-therapy-for-metastatic-prostate-cancer 2025-02-12T13:31:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmune-bio-advances-to-phase-ii-trial-of-inkmunetm-therapy-for-metastatic-prostate-cancer 2025-02-12T13:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/novel-gold-nanorod-therapy-shows-promise-for-cold-tumor-treatment-to-be-presented-at-canadian-melanoma-conference 2025-02-12T13:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-gold-nanorod-therapy-shows-promise-for-cold-tumor-treatment-to-be-presented-at-canadian-melanoma-conference 2025-02-12T13:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-evaluation-system-shows-promise-in-reducing-unnecessary-hospital-stays-for-colorectal-cancer-patients 2025-02-12T12:35:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-evaluation-system-shows-promise-in-reducing-unnecessary-hospital-stays-for-colorectal-cancer-patients 2025-02-12T12:35:36+00:00 hourly 0.9 https://trial.medpath.com/news/gender-gap-widens-in-hiv-life-expectancy-women-face-significant-disparities-despite-overall-improvements 2025-02-12T10:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gender-gap-widens-in-hiv-life-expectancy-women-face-significant-disparities-despite-overall-improvements 2025-02-12T10:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/bicara-launches-pivotal-phase-2-3-trial-of-novel-bifunctional-antibody-for-advanced-head-and-neck-cancer 2025-02-12T10:32:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bicara-launches-pivotal-phase-2-3-trial-of-novel-bifunctional-antibody-for-advanced-head-and-neck-cancer 2025-02-12T10:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-delays-review-of-sublocade-label-changes-for-opioid-use-disorder-treatment 2025-02-12T10:31:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-delays-review-of-sublocade-label-changes-for-opioid-use-disorder-treatment 2025-02-12T10:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/nih-collaboratory-trial-evaluates-novel-advance-care-planning-program-for-elderly-cancer-patients 2025-02-12T10:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-collaboratory-trial-evaluates-novel-advance-care-planning-program-for-elderly-cancer-patients 2025-02-12T10:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/bluejay-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-biotech-executive-mary-cromwell 2025-02-12T08:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bluejay-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-biotech-executive-mary-cromwell 2025-02-12T08:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-overtakes-us-as-global-leader-in-clinical-trial-volume-globaldata-analysis-reveals 2025-02-12T08:21:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-overtakes-us-as-global-leader-in-clinical-trial-volume-globaldata-analysis-reveals 2025-02-12T08:21:41+00:00 hourly 0.9 https://trial.medpath.com/news/aligos-therapeutics-secures-105m-financing-to-advance-hepatitis-b-drug-development 2025-02-12T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aligos-therapeutics-secures-105m-financing-to-advance-hepatitis-b-drug-development 2025-02-12T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/uniqure-launches-public-offering-to-advance-gene-therapy-pipeline 2025-02-12T05:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uniqure-launches-public-offering-to-advance-gene-therapy-pipeline 2025-02-12T05:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/arcus-biosciences-to-present-casdatifan-monotherapy-data-in-advanced-kidney-cancer-at-asco-gu-2025 2025-02-12T05:31:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcus-biosciences-to-present-casdatifan-monotherapy-data-in-advanced-kidney-cancer-at-asco-gu-2025 2025-02-12T05:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/terrain-biosciences-launches-ai-powered-rna-design-platform-with-9m-seed-funding 2025-02-12T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/terrain-biosciences-launches-ai-powered-rna-design-platform-with-9m-seed-funding 2025-02-12T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-alberta-s-novel-cancer-drug-zelenirstat-receives-fda-fast-track-designation 2025-02-12T04:32:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-alberta-s-novel-cancer-drug-zelenirstat-receives-fda-fast-track-designation 2025-02-12T04:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-lion-tcr-s-novel-mrna-based-tcr-t-cell-therapy-for-phase-2-trial-in-hbv-related-liver-cancer 2025-02-12T04:31:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-lion-tcr-s-novel-mrna-based-tcr-t-cell-therapy-for-phase-2-trial-in-hbv-related-liver-cancer 2025-02-12T04:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/alexion-launches-interactive-storybook-to-help-children-understand-rare-kidney-disease-ahus 2025-02-12T03:45:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alexion-launches-interactive-storybook-to-help-children-understand-rare-kidney-disease-ahus 2025-02-12T03:45:27+00:00 hourly 0.9 https://trial.medpath.com/news/biolab-holdings-advances-venous-leg-ulcer-treatment-with-irb-approval-for-membrane-wrap-trial 2025-02-12T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biolab-holdings-advances-venous-leg-ulcer-treatment-with-irb-approval-for-membrane-wrap-trial 2025-02-12T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/voyager-therapeutics-redirects-sod1-als-gene-therapy-development-after-preclinical-findings 2025-02-12T01:32:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/voyager-therapeutics-redirects-sod1-als-gene-therapy-development-after-preclinical-findings 2025-02-12T01:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/nih-study-single-dose-of-medi8852-antibody-shows-complete-protection-against-h5n1-avian-flu-in-primates 2025-02-12T01:32:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-study-single-dose-of-medi8852-antibody-shows-complete-protection-against-h5n1-avian-flu-in-primates 2025-02-12T01:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-faces-market-uncertainty-as-povorcitinib-phase-iii-trial-results-loom 2025-02-12T01:31:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-faces-market-uncertainty-as-povorcitinib-phase-iii-trial-results-loom 2025-02-12T01:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/inventiva-slashes-workforce-and-programs-to-focus-on-late-stage-mash-drug-lanifibranor 2025-02-12T01:31:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inventiva-slashes-workforce-and-programs-to-focus-on-late-stage-mash-drug-lanifibranor 2025-02-12T01:31:34+00:00 hourly 0.9 https://trial.medpath.com/news/european-study-shows-biosimilar-competition-drives-21-6-reduction-in-insulin-glargine-prices 2025-02-12T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-study-shows-biosimilar-competition-drives-21-6-reduction-in-insulin-glargine-prices 2025-02-12T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-trial-shows-promise-for-in-006-inhaled-covid-19-antibody-therapy 2025-02-12T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-trial-shows-promise-for-in-006-inhaled-covid-19-antibody-therapy 2025-02-12T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/travere-therapeutics-plans-snda-submission-for-filspari-to-treat-rare-kidney-disease-fsgs 2025-02-11T22:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/travere-therapeutics-plans-snda-submission-for-filspari-to-treat-rare-kidney-disease-fsgs 2025-02-11T22:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/ausperbio-completes-dosing-in-phase-iib-trial-of-novel-hepatitis-b-treatment-ahb-137 2025-02-11T22:32:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ausperbio-completes-dosing-in-phase-iib-trial-of-novel-hepatitis-b-treatment-ahb-137 2025-02-11T22:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/bleximenib-shows-promising-results-in-advanced-acute-leukemia-trial-with-kmt2a-and-npm1-mutations 2025-02-11T22:32:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bleximenib-shows-promising-results-in-advanced-acute-leukemia-trial-with-kmt2a-and-npm1-mutations 2025-02-11T22:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/global-neuroregeneration-therapy-market-set-to-reach-64-8-billion-by-2034-driven-by-ai-and-stem-cell-innovations 2025-02-11T22:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-neuroregeneration-therapy-market-set-to-reach-64-8-billion-by-2034-driven-by-ai-and-stem-cell-innovations 2025-02-11T22:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-brain-computer-interface-achieves-97-accuracy-in-speech-translation-wins-top-clinical-research-award 2025-02-11T22:31:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-brain-computer-interface-achieves-97-accuracy-in-speech-translation-wins-top-clinical-research-award 2025-02-11T22:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-s-ofev-nears-eu-approval-for-systemic-sclerosis-related-lung-disease 2025-02-11T20:31:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-s-ofev-nears-eu-approval-for-systemic-sclerosis-related-lung-disease 2025-02-11T20:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/novel-minimally-invasive-triple-t-therapy-shows-promise-in-treating-primary-aldosteronism 2025-02-11T20:01:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-minimally-invasive-triple-t-therapy-shows-promise-in-treating-primary-aldosteronism 2025-02-11T20:01:30+00:00 hourly 0.9 https://trial.medpath.com/news/novel-anti-platelet-drug-at-10-shows-promise-in-overcoming-clopidogrel-resistance 2025-02-11T19:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-anti-platelet-drug-at-10-shows-promise-in-overcoming-clopidogrel-resistance 2025-02-11T19:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/cosmos-health-s-novel-weight-management-device-ccx0722-enters-final-development-stage-targeting-2026-launch 2025-02-11T19:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cosmos-health-s-novel-weight-management-device-ccx0722-enters-final-development-stage-targeting-2026-launch 2025-02-11T19:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/octavian-therapeutics-emerges-with-new-brand-and-ps10m-fundraising-plan-for-neuropathic-pain-drug-development 2025-02-11T19:32:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/octavian-therapeutics-emerges-with-new-brand-and-ps10m-fundraising-plan-for-neuropathic-pain-drug-development 2025-02-11T19:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/pikaso-trial-investigates-metformin-for-preventing-post-acl-surgery-osteoarthritis 2025-02-11T19:31:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pikaso-trial-investigates-metformin-for-preventing-post-acl-surgery-osteoarthritis 2025-02-11T19:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/ifb-088-shows-promise-in-phase-2-trial-for-bulbar-onset-als-demonstrating-slower-disease-progression 2025-02-11T19:31:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ifb-088-shows-promise-in-phase-2-trial-for-bulbar-onset-als-demonstrating-slower-disease-progression 2025-02-11T19:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/inventiva-restructures-halves-workforce-to-focus-on-late-stage-mash-drug-lanifibranor 2025-02-11T19:31:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inventiva-restructures-halves-workforce-to-focus-on-late-stage-mash-drug-lanifibranor 2025-02-11T19:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/vancomycin-shows-promise-in-treating-psc-associated-inflammatory-bowel-disease 2025-02-11T19:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vancomycin-shows-promise-in-treating-psc-associated-inflammatory-bowel-disease 2025-02-11T19:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/goldman-sachs-downgrades-dynavax-on-competitive-pressures-in-shingles-and-hepatitis-b-markets 2025-02-11T19:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/goldman-sachs-downgrades-dynavax-on-competitive-pressures-in-shingles-and-hepatitis-b-markets 2025-02-11T19:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/abviro-initiates-nih-backed-human-challenge-trial-for-novel-dengue-therapy 2025-02-11T18:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abviro-initiates-nih-backed-human-challenge-trial-for-novel-dengue-therapy 2025-02-11T18:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/microbot-medical-secures-13m-funding-to-advance-revolutionary-endovascular-robotic-system 2025-02-11T18:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microbot-medical-secures-13m-funding-to-advance-revolutionary-endovascular-robotic-system 2025-02-11T18:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/allostem-cell-therapy-shows-80-efficacy-in-one-year-type-2-diabetes-trial 2025-02-11T17:32:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allostem-cell-therapy-shows-80-efficacy-in-one-year-type-2-diabetes-trial 2025-02-11T17:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/theraclion-s-sonovein-r-speedpulse-innovation-promises-faster-varicose-vein-treatment 2025-02-11T17:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theraclion-s-sonovein-r-speedpulse-innovation-promises-faster-varicose-vein-treatment 2025-02-11T17:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-mevrometostat-shows-promising-results-in-phase-i-prostate-cancer-trial 2025-02-11T17:01:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-mevrometostat-shows-promising-results-in-phase-i-prostate-cancer-trial 2025-02-11T17:01:48+00:00 hourly 0.9 https://trial.medpath.com/news/cereno-scientific-s-cs014-successfully-completes-first-phase-of-safety-trial-for-pulmonary-fibrosis-treatment 2025-02-11T16:37:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cereno-scientific-s-cs014-successfully-completes-first-phase-of-safety-trial-for-pulmonary-fibrosis-treatment 2025-02-11T16:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/kiora-pharmaceuticals-advances-kio-104-to-phase-2-trial-for-retinal-macular-edema-treatment 2025-02-11T16:36:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kiora-pharmaceuticals-advances-kio-104-to-phase-2-trial-for-retinal-macular-edema-treatment 2025-02-11T16:36:58+00:00 hourly 0.9 https://trial.medpath.com/news/combination-chemo-immunotherapy-shows-promise-in-bladder-preserving-treatment-for-muscle-invasive-cancer 2025-02-11T16:36:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combination-chemo-immunotherapy-shows-promise-in-bladder-preserving-treatment-for-muscle-invasive-cancer 2025-02-11T16:36:40+00:00 hourly 0.9 https://trial.medpath.com/news/yaqrit-advances-l-ornithine-phenylacetate-to-phase-3-for-acute-hepatic-encephalopathy-treatment 2025-02-11T16:36:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yaqrit-advances-l-ornithine-phenylacetate-to-phase-3-for-acute-hepatic-encephalopathy-treatment 2025-02-11T16:36:19+00:00 hourly 0.9 https://trial.medpath.com/news/eu-launches-multi-country-clinical-trial-assessment-pilot-to-streamline-approval-process 2025-02-11T16:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-launches-multi-country-clinical-trial-assessment-pilot-to-streamline-approval-process 2025-02-11T16:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-acquires-anthos-therapeutics-for-925m-aims-to-advance-novel-blood-thinner-abelacimab 2025-02-11T16:35:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-acquires-anthos-therapeutics-for-925m-aims-to-advance-novel-blood-thinner-abelacimab 2025-02-11T16:35:40+00:00 hourly 0.9 https://trial.medpath.com/news/usaid-funding-freeze-disrupts-global-clinical-trials-and-health-programs 2025-02-11T16:32:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usaid-funding-freeze-disrupts-global-clinical-trials-and-health-programs 2025-02-11T16:32:28+00:00 hourly 0.9 https://trial.medpath.com/news/fortrea-selected-to-lead-fda-clinical-trials-for-ai-powered-diabetic-retinopathy-detection-platform 2025-02-11T16:32:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fortrea-selected-to-lead-fda-clinical-trials-for-ai-powered-diabetic-retinopathy-detection-platform 2025-02-11T16:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/novel-hif-2a-inhibitor-casdatifan-shows-promise-in-advanced-kidney-cancer-phase-1-trial 2025-02-11T16:31:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-hif-2a-inhibitor-casdatifan-shows-promise-in-advanced-kidney-cancer-phase-1-trial 2025-02-11T16:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/lineage-cell-therapeutics-launches-dosed-study-for-novel-spinal-cord-injury-cell-therapy 2025-02-11T16:31:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lineage-cell-therapeutics-launches-dosed-study-for-novel-spinal-cord-injury-cell-therapy 2025-02-11T16:31:29+00:00 hourly 0.9 https://trial.medpath.com/news/enhanced-navigation-program-significantly-improves-timing-of-post-surgery-radiation-in-head-and-neck-cancer 2025-02-11T15:01:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enhanced-navigation-program-significantly-improves-timing-of-post-surgery-radiation-in-head-and-neck-cancer 2025-02-11T15:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/ultrasound-activated-nanoparticles-enable-precise-drug-delivery-to-deep-brain-regions-in-primates 2025-02-11T14:59:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultrasound-activated-nanoparticles-enable-precise-drug-delivery-to-deep-brain-regions-in-primates 2025-02-11T14:59:36+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-to-acquire-anthos-therapeutics-for-925m-advancing-novel-stroke-prevention-drug-abelacimab 2025-02-11T14:32:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-to-acquire-anthos-therapeutics-for-925m-advancing-novel-stroke-prevention-drug-abelacimab 2025-02-11T14:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/third-harmonic-bio-s-thb335-shows-promising-phase-1-results-for-chronic-urticaria-treatment 2025-02-11T14:31:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/third-harmonic-bio-s-thb335-shows-promising-phase-1-results-for-chronic-urticaria-treatment 2025-02-11T14:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-to-troriluzole-for-spinocerebellar-ataxia-treatment 2025-02-11T13:32:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-troriluzole-for-spinocerebellar-ataxia-treatment 2025-02-11T13:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/zeo-scientifix-advances-regenerative-medicine-portfolio-with-successful-phase-i-completion-of-zofintm 2025-02-11T13:31:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zeo-scientifix-advances-regenerative-medicine-portfolio-with-successful-phase-i-completion-of-zofintm 2025-02-11T13:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-healthcare-access-barriers-and-cardiovascular-risk-profiles-in-ibd-treatment-options 2025-02-11T12:21:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-healthcare-access-barriers-and-cardiovascular-risk-profiles-in-ibd-treatment-options 2025-02-11T12:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-success-industry-expert-outlines-key-strategies-for-better-site-engagement 2025-02-11T12:14:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-success-industry-expert-outlines-key-strategies-for-better-site-engagement 2025-02-11T12:14:56+00:00 hourly 0.9 https://trial.medpath.com/news/trump-s-tariffs-set-to-reshape-us-clinical-trial-landscape-and-drug-manufacturing 2025-02-11T10:51:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-s-tariffs-set-to-reshape-us-clinical-trial-landscape-and-drug-manufacturing 2025-02-11T10:51:25+00:00 hourly 0.9 https://trial.medpath.com/news/enhanced-monofocal-iols-show-promise-as-safe-alternative-for-glaucoma-patients 2025-02-11T10:45:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enhanced-monofocal-iols-show-promise-as-safe-alternative-for-glaucoma-patients 2025-02-11T10:45:18+00:00 hourly 0.9 https://trial.medpath.com/news/q32-bio-restructures-to-advance-bempikibart-development-for-alopecia-areata-treatment 2025-02-11T10:31:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/q32-bio-restructures-to-advance-bempikibart-development-for-alopecia-areata-treatment 2025-02-11T10:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/novel-tb-vaccines-and-ai-driven-solutions-show-promise-in-global-fight-against-tuberculosis 2025-02-11T10:31:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-tb-vaccines-and-ai-driven-solutions-show-promise-in-global-fight-against-tuberculosis 2025-02-11T10:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/purdue-innovates-partners-with-biobond-to-advance-novel-material-technologies-commercialization 2025-02-11T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/purdue-innovates-partners-with-biobond-to-advance-novel-material-technologies-commercialization 2025-02-11T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breast-cancer-rates-rise-disproportionately-among-minority-women-seer-data-shows 2025-02-11T08:29:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breast-cancer-rates-rise-disproportionately-among-minority-women-seer-data-shows 2025-02-11T08:29:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ibex-s-ai-powered-software-for-prostate-cancer-detection-with-99-6-accuracy 2025-02-11T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ibex-s-ai-powered-software-for-prostate-cancer-detection-with-99-6-accuracy 2025-02-11T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-seeks-ema-approval-for-first-oral-glp-1-diabetes-treatment 2025-02-11T07:31:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-seeks-ema-approval-for-first-oral-glp-1-diabetes-treatment 2025-02-11T07:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/inspira-s-bio-electronic-patch-shows-95-efficacy-in-preventing-bloodstream-infections 2025-02-11T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inspira-s-bio-electronic-patch-shows-95-efficacy-in-preventing-bloodstream-infections 2025-02-11T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/racial-disparities-persist-in-triple-negative-breast-cancer-trials-despite-treatment-advances 2025-02-11T06:32:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/racial-disparities-persist-in-triple-negative-breast-cancer-trials-despite-treatment-advances 2025-02-11T06:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/stellaromics-raises-new-funding-to-pioneer-3d-spatial-biology-platform-for-cancer-and-neuroscience-research 2025-02-11T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stellaromics-raises-new-funding-to-pioneer-3d-spatial-biology-platform-for-cancer-and-neuroscience-research 2025-02-11T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nih-trial-shows-home-based-peanut-butter-therapy-successfully-treats-high-threshold-peanut-allergies 2025-02-11T04:31:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-trial-shows-home-based-peanut-butter-therapy-successfully-treats-high-threshold-peanut-allergies 2025-02-11T04:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-in-advanced-talks-to-acquire-springworks-therapeutics-bridgebio-secures-eu-approval-for-attr-drug 2025-02-11T03:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-kgaa-in-advanced-talks-to-acquire-springworks-therapeutics-bridgebio-secures-eu-approval-for-attr-drug 2025-02-11T03:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/michigan-study-reveals-working-past-65-boosts-physical-and-mental-health-outcomes 2025-02-11T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/michigan-study-reveals-working-past-65-boosts-physical-and-mental-health-outcomes 2025-02-11T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/padcev-keytruda-combination-shows-sustained-survival-benefit-in-advanced-urothelial-cancer-trial 2025-02-11T02:31:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/padcev-keytruda-combination-shows-sustained-survival-benefit-in-advanced-urothelial-cancer-trial 2025-02-11T02:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/clearside-s-cls-ax-phase-2b-trial-data-shows-promise-in-treatment-naive-amd-patients 2025-02-11T02:01:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clearside-s-cls-ax-phase-2b-trial-data-shows-promise-in-treatment-naive-amd-patients 2025-02-11T02:01:26+00:00 hourly 0.9 https://trial.medpath.com/news/md-anderson-reports-breakthrough-in-metastatic-prostate-cancer-treatment-with-targeted-therapy 2025-02-11T01:32:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/md-anderson-reports-breakthrough-in-metastatic-prostate-cancer-treatment-with-targeted-therapy 2025-02-11T01:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/conv01-a-combination-therapy-shows-29-8-month-survival-in-advanced-prostate-cancer-trial 2025-02-11T01:31:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/conv01-a-combination-therapy-shows-29-8-month-survival-in-advanced-prostate-cancer-trial 2025-02-11T01:31:29+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-sites-face-growing-technology-burden-as-industry-pushes-for-greater-diversity-and-efficiency 2025-02-11T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-sites-face-growing-technology-burden-as-industry-pushes-for-greater-diversity-and-efficiency 2025-02-11T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/higher-dose-two-session-vaginal-brachytherapy-proves-effective-for-endometrial-cancer-treatment 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/higher-dose-two-session-vaginal-brachytherapy-proves-effective-for-endometrial-cancer-treatment 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cognitive-processing-therapy-shows-superior-efficacy-for-ptsd-treatment-in-landmark-japanese-study 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cognitive-processing-therapy-shows-superior-efficacy-for-ptsd-treatment-in-landmark-japanese-study 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gut-microbiome-profile-determines-broccoli-sprout-extract-s-effectiveness-in-prediabetes-treatment 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-microbiome-profile-determines-broccoli-sprout-extract-s-effectiveness-in-prediabetes-treatment 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pnkp-inhibitor-shows-promise-in-enhancing-radiation-therapy-for-colorectal-cancer 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pnkp-inhibitor-shows-promise-in-enhancing-radiation-therapy-for-colorectal-cancer 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-therapies-show-promise-in-reshaping-frontline-metastatic-rcc-treatment-landscape 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-therapies-show-promise-in-reshaping-frontline-metastatic-rcc-treatment-landscape 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-novel-treatment-for-rare-genetic-lipid-disorder-familial-chylomicronemia-syndrome 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-novel-treatment-for-rare-genetic-lipid-disorder-familial-chylomicronemia-syndrome 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/oragenics-and-brainbox-solutions-partner-to-develop-first-integrated-concussion-diagnosis-and-treatment-platform 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oragenics-and-brainbox-solutions-partner-to-develop-first-integrated-concussion-diagnosis-and-treatment-platform 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/double-dose-dolutegravir-shows-promise-in-reducing-hiv-viral-reservoir 2025-02-10T22:33:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/double-dose-dolutegravir-shows-promise-in-reducing-hiv-viral-reservoir 2025-02-10T22:33:21+00:00 hourly 0.9 https://trial.medpath.com/news/novel-car-t-cell-therapy-shows-97-response-rate-in-advanced-multiple-myeloma-trial 2025-02-10T22:33:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-car-t-cell-therapy-shows-97-response-rate-in-advanced-multiple-myeloma-trial 2025-02-10T22:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/hku-develops-revolutionary-oral-arsenic-treatment-for-rare-blood-cancer-with-97-cure-rate 2025-02-10T22:32:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hku-develops-revolutionary-oral-arsenic-treatment-for-rare-blood-cancer-with-97-cure-rate 2025-02-10T22:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/eu-expands-covid-19-vaccine-options-new-protein-based-vaccines-join-mrna-offerings-for-2024 2025-02-10T22:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-expands-covid-19-vaccine-options-new-protein-based-vaccines-join-mrna-offerings-for-2024 2025-02-10T22:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-shows-delgocitinib-cream-effective-for-adolescent-chronic-hand-eczema 2025-02-10T22:32:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-shows-delgocitinib-cream-effective-for-adolescent-chronic-hand-eczema 2025-02-10T22:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/triple-combination-of-envafolimab-suvemcitug-and-folfiri-shows-promise-in-advanced-colorectal-cancer 2025-02-10T22:31:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triple-combination-of-envafolimab-suvemcitug-and-folfiri-shows-promise-in-advanced-colorectal-cancer 2025-02-10T22:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/inventiva-restructures-to-focus-on-mash-drug-development-reports-eur96-6m-year-end-cash-position 2025-02-10T22:31:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inventiva-restructures-to-focus-on-mash-drug-development-reports-eur96-6m-year-end-cash-position 2025-02-10T22:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/novel-cd28-x-nectin-4-bispecific-antibody-shows-promise-in-advanced-bladder-cancer-treatment 2025-02-10T22:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-cd28-x-nectin-4-bispecific-antibody-shows-promise-in-advanced-bladder-cancer-treatment 2025-02-10T22:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/narsoplimab-shows-promising-real-world-outcomes-in-ta-tma-patients-at-2025-tandem-meetings 2025-02-10T20:01:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/narsoplimab-shows-promising-real-world-outcomes-in-ta-tma-patients-at-2025-tandem-meetings 2025-02-10T20:01:44+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-genomic-analysis-reveals-key-metastatic-pathways-and-drug-targets-in-thyroid-cancer 2025-02-10T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-genomic-analysis-reveals-key-metastatic-pathways-and-drug-targets-in-thyroid-cancer 2025-02-10T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cel-sci-advances-multikine-for-head-and-neck-cancer-with-fda-cleared-212-patient-registration-study 2025-02-10T19:32:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cel-sci-advances-multikine-for-head-and-neck-cancer-with-fda-cleared-212-patient-registration-study 2025-02-10T19:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-gender-gap-in-post-stroke-cardiac-care-women-receive-less-monitoring-and-fewer-cardiology-referrals 2025-02-10T19:31:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-gender-gap-in-post-stroke-cardiac-care-women-receive-less-monitoring-and-fewer-cardiology-referrals 2025-02-10T19:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/radiopharm-s-novel-brain-metastases-imaging-agent-shows-100-detection-rate-in-clinical-study 2025-02-10T19:31:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiopharm-s-novel-brain-metastases-imaging-agent-shows-100-detection-rate-in-clinical-study 2025-02-10T19:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/taurx-secures-119-million-investment-as-novel-tau-targeting-alzheimer-s-drug-advances-toward-regulatory-filing 2025-02-10T17:31:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taurx-secures-119-million-investment-as-novel-tau-targeting-alzheimer-s-drug-advances-toward-regulatory-filing 2025-02-10T17:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/nls-pharmaceutics-and-newamsterdam-pharma-file-mixed-securities-shelves-worth-75m-and-500m-respectively 2025-02-10T16:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nls-pharmaceutics-and-newamsterdam-pharma-file-mixed-securities-shelves-worth-75m-and-500m-respectively 2025-02-10T16:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/lonsurf-shows-promising-survival-benefits-for-stage-4-colorectal-cancer-patients-with-molecular-residual-disease 2025-02-10T16:36:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lonsurf-shows-promising-survival-benefits-for-stage-4-colorectal-cancer-patients-with-molecular-residual-disease 2025-02-10T16:36:03+00:00 hourly 0.9 https://trial.medpath.com/news/inovio-to-present-ino-3107-hpv-treatment-data-showing-complete-viral-clearance-at-aacr-io-conference 2025-02-10T16:35:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inovio-to-present-ino-3107-hpv-treatment-data-showing-complete-viral-clearance-at-aacr-io-conference 2025-02-10T16:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/ocean-biomedical-s-novel-cancer-immunotherapy-shows-promise-in-reversing-egfr-tki-resistance-in-lung-cancer 2025-02-10T16:35:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocean-biomedical-s-novel-cancer-immunotherapy-shows-promise-in-reversing-egfr-tki-resistance-in-lung-cancer 2025-02-10T16:35:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-status-to-erapa-for-familial-adenomatous-polyposis-treatment 2025-02-10T16:34:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-status-to-erapa-for-familial-adenomatous-polyposis-treatment 2025-02-10T16:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/greenwich-lifesciences-reports-46-hla-a-02-prevalence-in-flamingo-01-trial-for-breast-cancer-vaccine 2025-02-10T16:34:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greenwich-lifesciences-reports-46-hla-a-02-prevalence-in-flamingo-01-trial-for-breast-cancer-vaccine 2025-02-10T16:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-reports-strong-2024-growth-with-4-2b-revenue-outlines-ambitious-2025-pipeline-milestones 2025-02-10T16:33:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-reports-strong-2024-growth-with-4-2b-revenue-outlines-ambitious-2025-pipeline-milestones 2025-02-10T16:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/washu-medicine-launches-groundbreaking-trial-of-remternetug-to-prevent-early-onset-alzheimer-s 2025-02-10T16:33:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/washu-medicine-launches-groundbreaking-trial-of-remternetug-to-prevent-early-onset-alzheimer-s 2025-02-10T16:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/bcg-shortage-continues-to-shape-bladder-cancer-treatment-landscape-despite-new-therapy-approvals 2025-02-10T16:32:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bcg-shortage-continues-to-shape-bladder-cancer-treatment-landscape-despite-new-therapy-approvals 2025-02-10T16:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approvals-expand-amivantamab-s-role-in-egfr-mutated-nsclc-treatment 2025-02-10T16:32:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approvals-expand-amivantamab-s-role-in-egfr-mutated-nsclc-treatment 2025-02-10T16:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-shows-promising-renal-benefits-in-type-2-diabetes-patients-through-surpass-trials-analysis 2025-02-10T16:32:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tirzepatide-shows-promising-renal-benefits-in-type-2-diabetes-patients-through-surpass-trials-analysis 2025-02-10T16:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/iview-therapeutics-novel-dry-eye-treatment-shows-promising-results-in-phase-1-2-trial 2025-02-10T16:32:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iview-therapeutics-novel-dry-eye-treatment-shows-promising-results-in-phase-1-2-trial 2025-02-10T16:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/bharat-biotech-subsidiary-launches-world-s-first-diva-marker-lumpy-skin-disease-vaccine 2025-02-10T14:31:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bharat-biotech-subsidiary-launches-world-s-first-diva-marker-lumpy-skin-disease-vaccine 2025-02-10T14:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-superior-survival-outcomes-for-cll-and-mcl-patients-at-academic-cancer-centers 2025-02-10T14:03:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-superior-survival-outcomes-for-cll-and-mcl-patients-at-academic-cancer-centers 2025-02-10T14:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/pliant-therapeutics-halts-ipf-drug-trial-following-safety-concerns-stock-plummets 2025-02-10T14:02:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pliant-therapeutics-halts-ipf-drug-trial-following-safety-concerns-stock-plummets 2025-02-10T14:02:14+00:00 hourly 0.9 https://trial.medpath.com/news/pliant-therapeutics-halts-beacon-ipf-trial-following-safety-board-review 2025-02-10T14:01:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pliant-therapeutics-halts-beacon-ipf-trial-following-safety-board-review 2025-02-10T14:01:58+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-plans-fda-submission-for-cordstrom-in-rare-skin-disease-rdeb 2025-02-10T14:01:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmune-bio-plans-fda-submission-for-cordstrom-in-rare-skin-disease-rdeb 2025-02-10T14:01:45+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-success-gtx-104-shows-promise-in-treating-brain-hemorrhage-with-reduced-hypotension-risk 2025-02-10T13:37:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-success-gtx-104-shows-promise-in-treating-brain-hemorrhage-with-reduced-hypotension-risk 2025-02-10T13:37:21+00:00 hourly 0.9 https://trial.medpath.com/news/actuate-therapeutics-elraglusib-shows-promise-in-pancreatic-cancer-as-ipo-lock-up-expires 2025-02-10T13:36:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actuate-therapeutics-elraglusib-shows-promise-in-pancreatic-cancer-as-ipo-lock-up-expires 2025-02-10T13:36:03+00:00 hourly 0.9 https://trial.medpath.com/news/olix-and-eli-lilly-forge-630m-deal-for-novel-rnai-therapy-targeting-mash-and-obesity 2025-02-10T13:35:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olix-and-eli-lilly-forge-630m-deal-for-novel-rnai-therapy-targeting-mash-and-obesity 2025-02-10T13:35:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-shanghai-henlius-biotech-s-novel-als-drug-hlx99 2025-02-10T13:35:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-shanghai-henlius-biotech-s-novel-als-drug-hlx99 2025-02-10T13:35:27+00:00 hourly 0.9 https://trial.medpath.com/news/scotland-rejects-lecanemab-for-nhs-coverage-citing-cost-and-benefit-uncertainties 2025-02-10T13:35:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scotland-rejects-lecanemab-for-nhs-coverage-citing-cost-and-benefit-uncertainties 2025-02-10T13:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/cardiogeni-secures-ps20m-investment-for-heart-failure-drug-trials-in-uae-partnership 2025-02-10T13:34:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardiogeni-secures-ps20m-investment-for-heart-failure-drug-trials-in-uae-partnership 2025-02-10T13:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/plasmid-dna-manufacturing-market-set-to-reach-11-33-billion-by-2034-amid-gene-therapy-boom 2025-02-10T13:28:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plasmid-dna-manufacturing-market-set-to-reach-11-33-billion-by-2034-amid-gene-therapy-boom 2025-02-10T13:28:50+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-coo-stuart-arbuckle-to-retire-company-announces-key-leadership-changes 2025-02-10T12:42:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-coo-stuart-arbuckle-to-retire-company-announces-key-leadership-changes 2025-02-10T12:42:53+00:00 hourly 0.9 https://trial.medpath.com/news/orca-t-cell-therapy-shows-superior-outcomes-in-phase-3-trial-for-blood-cancer-patients 2025-02-10T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orca-t-cell-therapy-shows-superior-outcomes-in-phase-3-trial-for-blood-cancer-patients 2025-02-10T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-part-b-psychiatrist-coverage-drops-16-8-despite-growing-mental-health-workforce 2025-02-10T12:00:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-part-b-psychiatrist-coverage-drops-16-8-despite-growing-mental-health-workforce 2025-02-10T12:00:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-outlines-requirements-for-mmj-002-first-natural-cannabis-drug-for-huntington-s-disease 2025-02-10T11:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-outlines-requirements-for-mmj-002-first-natural-cannabis-drug-for-huntington-s-disease 2025-02-10T11:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/medincell-s-olanzapine-lai-phase-3-trial-completes-triggering-5m-milestone-payment-from-teva 2025-02-10T11:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medincell-s-olanzapine-lai-phase-3-trial-completes-triggering-5m-milestone-payment-from-teva 2025-02-10T11:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/bictegravir-ftc-taf-shows-efficacy-in-hiv-patients-with-nrti-resistance-after-pi-based-therapy-switch 2025-02-10T11:08:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bictegravir-ftc-taf-shows-efficacy-in-hiv-patients-with-nrti-resistance-after-pi-based-therapy-switch 2025-02-10T11:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/bioray-s-novel-dual-epitope-adc-drug-br111-advances-to-clinical-trials-for-cancer-treatment 2025-02-10T11:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioray-s-novel-dual-epitope-adc-drug-br111-advances-to-clinical-trials-for-cancer-treatment 2025-02-10T11:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/pyc-therapeutics-advances-novel-kidney-drug-to-first-human-clinical-trials 2025-02-10T11:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pyc-therapeutics-advances-novel-kidney-drug-to-first-human-clinical-trials 2025-02-10T11:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/esmo-guidelines-include-sugemalimab-as-first-line-nsclc-therapy-marking-major-treatment-advancement 2025-02-10T11:07:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esmo-guidelines-include-sugemalimab-as-first-line-nsclc-therapy-marking-major-treatment-advancement 2025-02-10T11:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/cbl-514-shows-promising-results-in-phase-2b-trial-for-non-surgical-fat-reduction 2025-02-10T11:06:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cbl-514-shows-promising-results-in-phase-2b-trial-for-non-surgical-fat-reduction 2025-02-10T11:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/acelink-s-oral-gcs-inhibitor-shows-promising-phase-2-results-in-fabry-disease-treatment 2025-02-10T11:05:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acelink-s-oral-gcs-inhibitor-shows-promising-phase-2-results-in-fabry-disease-treatment 2025-02-10T11:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/uk-mhra-approves-winlevi-r-first-novel-acne-treatment-in-40-years 2025-02-10T11:05:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-mhra-approves-winlevi-r-first-novel-acne-treatment-in-40-years 2025-02-10T11:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-sanofi-s-enjaymo-first-targeted-therapy-for-rare-blood-disorder-cad 2025-02-10T11:05:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-sanofi-s-enjaymo-first-targeted-therapy-for-rare-blood-disorder-cad 2025-02-10T11:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/gyder-surgical-secures-fda-clearance-for-novel-hip-replacement-navigation-system 2025-02-10T11:04:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gyder-surgical-secures-fda-clearance-for-novel-hip-replacement-navigation-system 2025-02-10T11:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/seragem-s-master-v7-massage-device-receives-fda-approval-for-multiple-therapeutic-indications 2025-02-10T11:04:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seragem-s-master-v7-massage-device-receives-fda-approval-for-multiple-therapeutic-indications 2025-02-10T11:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/medpacto-advances-vactosertib-to-phase-2-trial-for-pediatric-osteosarcoma-treatment-in-us 2025-02-10T11:04:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medpacto-advances-vactosertib-to-phase-2-trial-for-pediatric-osteosarcoma-treatment-in-us 2025-02-10T11:04:14+00:00 hourly 0.9 https://trial.medpath.com/news/tegoprubart-successfully-used-in-second-pig-to-human-kidney-xenotransplant-at-mgh 2025-02-10T11:03:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tegoprubart-successfully-used-in-second-pig-to-human-kidney-xenotransplant-at-mgh 2025-02-10T11:03:12+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-launches-generic-ezetimibe-competing-with-2-7b-zetia-market 2025-02-10T11:02:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amneal-launches-generic-ezetimibe-competing-with-2-7b-zetia-market 2025-02-10T11:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/modified-short-course-tb-treatment-shows-79-success-rate-in-dominican-republic-study 2025-02-10T11:02:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modified-short-course-tb-treatment-shows-79-success-rate-in-dominican-republic-study 2025-02-10T11:02:36+00:00 hourly 0.9 https://trial.medpath.com/news/jak-inhibitors-show-promising-long-term-safety-and-efficacy-in-atopic-dermatitis-treatment-yale-expert-reports 2025-02-10T11:01:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jak-inhibitors-show-promising-long-term-safety-and-efficacy-in-atopic-dermatitis-treatment-yale-expert-reports 2025-02-10T11:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/st-joseph-s-candler-pioneers-novel-dosing-study-for-metastatic-breast-cancer-treatment 2025-02-10T11:00:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/st-joseph-s-candler-pioneers-novel-dosing-study-for-metastatic-breast-cancer-treatment 2025-02-10T11:00:33+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-communication-freeze-disrupts-clinical-trials-and-public-health-updates-senators-demand-immediate-action 2025-02-10T11:00:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hhs-communication-freeze-disrupts-clinical-trials-and-public-health-updates-senators-demand-immediate-action 2025-02-10T11:00:16+00:00 hourly 0.9 https://trial.medpath.com/news/luzhu-biotech-s-novel-herpes-zoster-vaccine-advances-as-nmpa-accepts-regulatory-filing 2025-02-10T10:59:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/luzhu-biotech-s-novel-herpes-zoster-vaccine-advances-as-nmpa-accepts-regulatory-filing 2025-02-10T10:59:41+00:00 hourly 0.9 https://trial.medpath.com/news/mangoceuticals-advances-h1n1-study-and-expands-research-to-h5n1-influenza 2025-02-10T10:59:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mangoceuticals-advances-h1n1-study-and-expands-research-to-h5n1-influenza 2025-02-10T10:59:25+00:00 hourly 0.9 https://trial.medpath.com/news/wvu-medicine-leads-groundbreaking-trial-of-endoscopic-procedure-to-maintain-glp-1-weight-loss 2025-02-10T10:59:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wvu-medicine-leads-groundbreaking-trial-of-endoscopic-procedure-to-maintain-glp-1-weight-loss 2025-02-10T10:59:03+00:00 hourly 0.9 https://trial.medpath.com/news/neuralink-s-brain-computer-interface-shows-promise-after-one-year-three-patients-regain-digital-control 2025-02-10T10:58:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuralink-s-brain-computer-interface-shows-promise-after-one-year-three-patients-regain-digital-control 2025-02-10T10:58:44+00:00 hourly 0.9 https://trial.medpath.com/news/pembrolizumab-shows-promise-in-advanced-clear-cell-gynecologic-cancer-peacocc-trial-reports 2025-02-10T10:58:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pembrolizumab-shows-promise-in-advanced-clear-cell-gynecologic-cancer-peacocc-trial-reports 2025-02-10T10:58:24+00:00 hourly 0.9 https://trial.medpath.com/news/extended-time-window-for-alteplase-shows-breakthrough-results-in-late-stage-stroke-treatment 2025-02-10T10:58:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/extended-time-window-for-alteplase-shows-breakthrough-results-in-late-stage-stroke-treatment 2025-02-10T10:58:01+00:00 hourly 0.9 https://trial.medpath.com/news/gain-therapeutics-to-present-phase-1-data-for-novel-parkinson-s-drug-gt-02287-at-mjff-conference 2025-02-10T10:56:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gain-therapeutics-to-present-phase-1-data-for-novel-parkinson-s-drug-gt-02287-at-mjff-conference 2025-02-10T10:56:36+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trials-support-immunotherapy-first-approach-in-advanced-braf-melanoma-treatment 2025-02-10T10:55:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trials-support-immunotherapy-first-approach-in-advanced-braf-melanoma-treatment 2025-02-10T10:55:28+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nasal-spray-cyr-064-enters-trial-for-parkinson-s-related-smell-loss 2025-02-10T10:55:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-nasal-spray-cyr-064-enters-trial-for-parkinson-s-related-smell-loss 2025-02-10T10:55:10+00:00 hourly 0.9 https://trial.medpath.com/news/faron-pharmaceuticals-secures-eur12m-to-advance-promising-mds-treatment-bexmarilimab 2025-02-10T10:54:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faron-pharmaceuticals-secures-eur12m-to-advance-promising-mds-treatment-bexmarilimab 2025-02-10T10:54:09+00:00 hourly 0.9 https://trial.medpath.com/news/adjuvant-pd-1-inhibitors-show-promise-in-stage-iib-c-melanoma-treatment-keynote-716-and-checkmate-76k-trials-reveal 2025-02-10T10:52:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adjuvant-pd-1-inhibitors-show-promise-in-stage-iib-c-melanoma-treatment-keynote-716-and-checkmate-76k-trials-reveal 2025-02-10T10:52:33+00:00 hourly 0.9 https://trial.medpath.com/news/dana-farber-s-experimental-kidney-cancer-vaccine-shows-lasting-protection-after-three-years 2025-02-10T10:52:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dana-farber-s-experimental-kidney-cancer-vaccine-shows-lasting-protection-after-three-years 2025-02-10T10:52:15+00:00 hourly 0.9 https://trial.medpath.com/news/vetigenics-secures-6m-seed-funding-to-advance-pet-focused-antibody-therapeutics-pipeline 2025-02-10T10:51:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vetigenics-secures-6m-seed-funding-to-advance-pet-focused-antibody-therapeutics-pipeline 2025-02-10T10:51:52+00:00 hourly 0.9 https://trial.medpath.com/news/escape-mevo-trial-endovascular-thrombectomy-shows-no-added-benefit-for-medium-vessel-occlusion-stroke 2025-02-10T10:51:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/escape-mevo-trial-endovascular-thrombectomy-shows-no-added-benefit-for-medium-vessel-occlusion-stroke 2025-02-10T10:51:27+00:00 hourly 0.9 https://trial.medpath.com/news/ai-in-oncology-leading-oncologist-outlines-vision-for-clinician-ai-partnership-in-cancer-care 2025-02-10T10:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-in-oncology-leading-oncologist-outlines-vision-for-clinician-ai-partnership-in-cancer-care 2025-02-10T10:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/patient-journey-highlights-evolution-in-egfr-mutated-nsclc-treatment-landscape 2025-02-10T10:50:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-journey-highlights-evolution-in-egfr-mutated-nsclc-treatment-landscape 2025-02-10T10:50:55+00:00 hourly 0.9 https://trial.medpath.com/news/toleranzia-secures-swedish-regulatory-approval-for-tol2-clinical-trial-in-myasthenia-gravis 2025-02-10T10:49:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/toleranzia-secures-swedish-regulatory-approval-for-tol2-clinical-trial-in-myasthenia-gravis 2025-02-10T10:49:24+00:00 hourly 0.9 https://trial.medpath.com/news/eleva-partners-with-3pbiovian-to-scale-production-of-novel-complement-modulator-for-rare-diseases 2025-02-10T10:48:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eleva-partners-with-3pbiovian-to-scale-production-of-novel-complement-modulator-for-rare-diseases 2025-02-10T10:48:57+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-study-reveals-origins-of-post-car-t-myeloid-neoplasms-suggesting-similarities-to-known-treatment-related-malignancies 2025-02-10T10:48:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-study-reveals-origins-of-post-car-t-myeloid-neoplasms-suggesting-similarities-to-known-treatment-related-malignancies 2025-02-10T10:48:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-mb-105-for-cd5-blood-cancer-treatment 2025-02-10T10:47:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-mb-105-for-cd5-blood-cancer-treatment 2025-02-10T10:47:57+00:00 hourly 0.9 https://trial.medpath.com/news/conduit-pharmaceuticals-advances-to-phase-ii-of-ai-driven-drug-development-partnership 2025-02-10T10:47:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/conduit-pharmaceuticals-advances-to-phase-ii-of-ai-driven-drug-development-partnership 2025-02-10T10:47:41+00:00 hourly 0.9 https://trial.medpath.com/news/alumis-and-acelyrin-announce-merger-deal-suspend-phase-iii-plans-for-lonigutamab 2025-02-10T10:47:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alumis-and-acelyrin-announce-merger-deal-suspend-phase-iii-plans-for-lonigutamab 2025-02-10T10:47:29+00:00 hourly 0.9 https://trial.medpath.com/news/eyp-1901-shows-promise-in-wet-amd-and-dme-trials-with-significant-reduction-in-treatment-burden 2025-02-10T10:47:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eyp-1901-shows-promise-in-wet-amd-and-dme-trials-with-significant-reduction-in-treatment-burden 2025-02-10T10:47:10+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-safety-study-shows-comparable-colectomy-rates-between-golimumab-and-other-anti-tnf-therapies-in-ulcerative-colitis 2025-02-10T10:46:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-safety-study-shows-comparable-colectomy-rates-between-golimumab-and-other-anti-tnf-therapies-in-ulcerative-colitis 2025-02-10T10:46:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-lumenis-optilift-novel-device-shows-promise-in-treating-lower-lid-laxity-and-blinking-disorders 2025-02-10T10:46:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-lumenis-optilift-novel-device-shows-promise-in-treating-lower-lid-laxity-and-blinking-disorders 2025-02-10T10:46:39+00:00 hourly 0.9 https://trial.medpath.com/news/brazilian-trial-compares-metformin-vs-insulin-for-gestational-diabetes-management 2025-02-10T10:46:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brazilian-trial-compares-metformin-vs-insulin-for-gestational-diabetes-management 2025-02-10T10:46:21+00:00 hourly 0.9 https://trial.medpath.com/news/dha-launches-groundbreaking-platform-trial-to-evaluate-multiple-ptsd-treatments-for-military-personnel 2025-02-10T10:42:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dha-launches-groundbreaking-platform-trial-to-evaluate-multiple-ptsd-treatments-for-military-personnel 2025-02-10T10:42:44+00:00 hourly 0.9 https://trial.medpath.com/news/hlb-advances-cancer-drug-pipeline-rivoceranib-fda-decision-due-march-plans-rly-4008-development 2025-02-10T10:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hlb-advances-cancer-drug-pipeline-rivoceranib-fda-decision-due-march-plans-rly-4008-development 2025-02-10T10:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/replicate-s-single-dose-rna-rabies-vaccine-shows-promise-in-phase-i-trial 2025-02-10T10:36:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/replicate-s-single-dose-rna-rabies-vaccine-shows-promise-in-phase-i-trial 2025-02-10T10:36:05+00:00 hourly 0.9 https://trial.medpath.com/news/photopharmics-reaches-50-enrollment-milestone-in-phase-3-trial-testing-light-therapy-for-parkinson-s-disease 2025-02-10T10:35:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/photopharmics-reaches-50-enrollment-milestone-in-phase-3-trial-testing-light-therapy-for-parkinson-s-disease 2025-02-10T10:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/epcore-nhl-2-trial-shows-promise-combining-chemotherapy-and-immunotherapy-for-dlbcl 2025-02-10T10:35:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epcore-nhl-2-trial-shows-promise-combining-chemotherapy-and-immunotherapy-for-dlbcl 2025-02-10T10:35:24+00:00 hourly 0.9 https://trial.medpath.com/news/ema-issues-new-guidelines-for-clinical-development-of-advanced-therapy-medicinal-products 2025-02-10T10:35:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-issues-new-guidelines-for-clinical-development-of-advanced-therapy-medicinal-products 2025-02-10T10:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-novel-antibiotic-combination-emblaveo-for-complex-abdominal-infections 2025-02-10T10:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-novel-antibiotic-combination-emblaveo-for-complex-abdominal-infections 2025-02-10T10:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/scholar-rock-seeks-fda-approval-for-novel-sma-add-on-therapy-apitegromab 2025-02-10T10:31:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scholar-rock-seeks-fda-approval-for-novel-sma-add-on-therapy-apitegromab 2025-02-10T10:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-orlynvahtm-first-new-oral-treatment-for-uncomplicated-utis-in-25-years 2025-02-10T10:31:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-orlynvahtm-first-new-oral-treatment-for-uncomplicated-utis-in-25-years 2025-02-10T10:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-mim8-shows-promise-in-phase-iii-pediatric-hemophilia-a-trial 2025-02-10T10:30:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-mim8-shows-promise-in-phase-iii-pediatric-hemophilia-a-trial 2025-02-10T10:30:46+00:00 hourly 0.9 https://trial.medpath.com/news/novel-bispecific-antibody-kn046-plus-lenvatinib-shows-promise-in-advanced-liver-cancer-treatment 2025-02-10T10:30:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-bispecific-antibody-kn046-plus-lenvatinib-shows-promise-in-advanced-liver-cancer-treatment 2025-02-10T10:30:23+00:00 hourly 0.9 https://trial.medpath.com/news/spectral-ai-completes-pivotal-burn-study-analysis-plans-fda-de-novo-submission-for-ai-powered-wound-assessment-system 2025-02-10T10:30:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spectral-ai-completes-pivotal-burn-study-analysis-plans-fda-de-novo-submission-for-ai-powered-wound-assessment-system 2025-02-10T10:30:05+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-receives-novel-stem-cell-therapy-in-groundbreaking-sjogren-s-disease-trial 2025-02-10T10:29:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-receives-novel-stem-cell-therapy-in-groundbreaking-sjogren-s-disease-trial 2025-02-10T10:29:21+00:00 hourly 0.9 https://trial.medpath.com/news/telemedicine-based-lifestyle-intervention-shows-limited-benefits-for-patients-with-chd-and-type-2-diabetes 2025-02-10T10:28:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telemedicine-based-lifestyle-intervention-shows-limited-benefits-for-patients-with-chd-and-type-2-diabetes 2025-02-10T10:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/quince-therapeutics-phase-3-neat-trial-for-ataxia-telangiectasia-reaches-50-enrollment-milestone 2025-02-10T10:28:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quince-therapeutics-phase-3-neat-trial-for-ataxia-telangiectasia-reaches-50-enrollment-milestone 2025-02-10T10:28:33+00:00 hourly 0.9 https://trial.medpath.com/news/xairos-secures-1-9m-spacewerx-contract-for-quantum-optical-timing-system-development 2025-02-10T10:28:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xairos-secures-1-9m-spacewerx-contract-for-quantum-optical-timing-system-development 2025-02-10T10:28:09+00:00 hourly 0.9 https://trial.medpath.com/news/conduit-pharmaceuticals-advances-ai-driven-drug-development-through-phase-ii-sarborg-collaboration 2025-02-10T10:27:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/conduit-pharmaceuticals-advances-ai-driven-drug-development-through-phase-ii-sarborg-collaboration 2025-02-10T10:27:50+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-drug-semaglutide-shows-promise-in-alcohol-addiction-treatment-study-at-cu 2025-02-10T10:27:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-drug-semaglutide-shows-promise-in-alcohol-addiction-treatment-study-at-cu 2025-02-10T10:27:05+00:00 hourly 0.9 https://trial.medpath.com/news/ema-accepts-bio-thera-s-marketing-application-for-bat2506-first-chinese-developed-golimumab-biosimilar 2025-02-10T10:26:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-accepts-bio-thera-s-marketing-application-for-bat2506-first-chinese-developed-golimumab-biosimilar 2025-02-10T10:26:43+00:00 hourly 0.9 https://trial.medpath.com/news/rns60-shows-promising-results-in-phase-2-stroke-trial-reducing-brain-tissue-loss-by-50 2025-02-10T10:25:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rns60-shows-promising-results-in-phase-2-stroke-trial-reducing-brain-tissue-loss-by-50 2025-02-10T10:25:58+00:00 hourly 0.9 https://trial.medpath.com/news/zenas-biopharma-launches-phase-2-trial-of-novel-b-cell-targeting-therapy-for-relapsing-ms 2025-02-10T10:25:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zenas-biopharma-launches-phase-2-trial-of-novel-b-cell-targeting-therapy-for-relapsing-ms 2025-02-10T10:25:36+00:00 hourly 0.9 https://trial.medpath.com/news/alivedx-submits-fda-510-k-application-for-novel-celiac-disease-multiplex-diagnostic-array 2025-02-10T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alivedx-submits-fda-510-k-application-for-novel-celiac-disease-multiplex-diagnostic-array 2025-02-10T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/foresee-pharmaceuticals-to-present-phase-3-katana-studies-of-novel-prostate-cancer-treatment-at-asco-gu-2025 2025-02-10T08:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foresee-pharmaceuticals-to-present-phase-3-katana-studies-of-novel-prostate-cancer-treatment-at-asco-gu-2025 2025-02-10T08:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/alterity-therapeutics-secures-a-40m-funding-to-accelerate-msa-drug-development 2025-02-10T07:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alterity-therapeutics-secures-a-40m-funding-to-accelerate-msa-drug-development 2025-02-10T07:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-revolution-in-drug-discovery-computing-power-poised-to-transform-pharmaceutical-development 2025-02-10T07:17:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-revolution-in-drug-discovery-computing-power-poised-to-transform-pharmaceutical-development 2025-02-10T07:17:40+00:00 hourly 0.9 https://trial.medpath.com/news/experts-chart-future-direction-of-marginal-zone-lymphoma-research-at-2024-workshop 2025-02-10T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experts-chart-future-direction-of-marginal-zone-lymphoma-research-at-2024-workshop 2025-02-10T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sebetralstat-shows-promise-as-first-oral-treatment-for-hae-attacks-including-breakthrough-episodes-during-prophylaxis 2025-02-10T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sebetralstat-shows-promise-as-first-oral-treatment-for-hae-attacks-including-breakthrough-episodes-during-prophylaxis 2025-02-10T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-clinical-trials-for-first-ever-treatment-of-jordan-s-syndrome-a-rare-neurodevelopmental-disorder 2025-02-10T06:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-clinical-trials-for-first-ever-treatment-of-jordan-s-syndrome-a-rare-neurodevelopmental-disorder 2025-02-10T06:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-reveals-optimal-antibiotic-treatments-for-acute-pyelonephritis 2025-02-10T06:23:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meta-analysis-reveals-optimal-antibiotic-treatments-for-acute-pyelonephritis 2025-02-10T06:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-major-disparities-in-us-health-plan-coverage-of-pharmacogenetic-testing 2025-02-10T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-major-disparities-in-us-health-plan-coverage-of-pharmacogenetic-testing 2025-02-10T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-air-reports-34-revenue-growth-and-expands-global-market-access-with-ce-mark-for-lungfit-ph 2025-02-10T04:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-air-reports-34-revenue-growth-and-expands-global-market-access-with-ce-mark-for-lungfit-ph 2025-02-10T04:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-launches-clinical-trial-of-novel-psychedelic-for-postpartum-depression 2025-02-10T02:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleveland-clinic-launches-clinical-trial-of-novel-psychedelic-for-postpartum-depression 2025-02-10T02:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-ipsen-s-iqirvo-first-dual-ppar-agonist-for-primary-biliary-cholangitis 2025-02-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-ipsen-s-iqirvo-first-dual-ppar-agonist-for-primary-biliary-cholangitis 2025-02-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/adipose-derived-stem-cell-injections-show-promise-in-treating-inflammatory-eye-diseases 2025-02-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adipose-derived-stem-cell-injections-show-promise-in-treating-inflammatory-eye-diseases 2025-02-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bimzelx-s-novel-dual-il-17-inhibition-mechanism-drives-five-fda-approvals-across-inflammatory-conditions 2025-02-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bimzelx-s-novel-dual-il-17-inhibition-mechanism-drives-five-fda-approvals-across-inflammatory-conditions 2025-02-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/diagnostic-testing-emerges-as-critical-success-factor-in-adc-development-for-cancer-treatment 2025-02-09T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diagnostic-testing-emerges-as-critical-success-factor-in-adc-development-for-cancer-treatment 2025-02-09T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/targeted-therapies-and-immunotherapy-advances-in-non-small-cell-lung-cancer-a-comprehensive-review 2025-02-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/targeted-therapies-and-immunotherapy-advances-in-non-small-cell-lung-cancer-a-comprehensive-review 2025-02-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/national-study-shows-equal-effectiveness-of-different-dementia-care-delivery-models 2025-02-09T11:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/national-study-shows-equal-effectiveness-of-different-dementia-care-delivery-models 2025-02-09T11:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-clinical-trials-underestimate-quality-of-life-impact-in-relapsed-refractory-multiple-myeloma 2025-02-09T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-clinical-trials-underestimate-quality-of-life-impact-in-relapsed-refractory-multiple-myeloma 2025-02-09T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-study-reveals-critical-underutilization-of-secondary-prevention-medications-for-cardiovascular-disease 2025-02-09T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-study-reveals-critical-underutilization-of-secondary-prevention-medications-for-cardiovascular-disease 2025-02-09T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-machine-learning-models-show-promise-in-predicting-ckd-progression-to-kidney-failure 2025-02-09T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-machine-learning-models-show-promise-in-predicting-ckd-progression-to-kidney-failure 2025-02-09T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-launches-skyline-four-year-prevention-trial-for-gantenerumab-in-early-stage-alzheimer-s 2025-02-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-launches-skyline-four-year-prevention-trial-for-gantenerumab-in-early-stage-alzheimer-s 2025-02-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/deciphera-s-qinlock-fails-phase-3-trial-in-second-line-gist-shares-plummet-75 2025-02-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deciphera-s-qinlock-fails-phase-3-trial-in-second-line-gist-shares-plummet-75 2025-02-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/motion-control-running-shoes-reduce-injury-risk-in-runners-with-pronated-feet-study-shows 2025-02-08T17:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/motion-control-running-shoes-reduce-injury-risk-in-runners-with-pronated-feet-study-shows 2025-02-08T17:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/usaid-funding-freeze-threatens-hiv-treatment-programs-across-africa 2025-02-08T12:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usaid-funding-freeze-threatens-hiv-treatment-programs-across-africa 2025-02-08T12:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/experts-highlight-critical-link-between-schizophrenia-and-substance-use-disorders-call-for-integrated-treatment-approach 2025-02-08T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experts-highlight-critical-link-between-schizophrenia-and-substance-use-disorders-call-for-integrated-treatment-approach 2025-02-08T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-onc-ai-s-ai-powered-cancer-prognosis-tool 2025-02-08T00:01:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-onc-ai-s-ai-powered-cancer-prognosis-tool 2025-02-08T00:01:26+00:00 hourly 0.9 https://trial.medpath.com/news/lecanemab-shows-27-cognitive-decline-reduction-in-alzheimer-s-trial-safety-concerns-emerge 2025-02-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lecanemab-shows-27-cognitive-decline-reduction-in-alzheimer-s-trial-safety-concerns-emerge 2025-02-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-and-pfizer-launch-competitively-priced-sglt2-inhibitor-steglatro-for-type-2-diabetes 2025-02-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-and-pfizer-launch-competitively-priced-sglt2-inhibitor-steglatro-for-type-2-diabetes 2025-02-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ema-s-chmp-recommends-approval-of-novartis-jetrea-for-vitreomacular-traction-treatment 2025-02-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-s-chmp-recommends-approval-of-novartis-jetrea-for-vitreomacular-traction-treatment 2025-02-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-and-philogen-complete-enrollment-for-pivotal-phase-iii-fibrosarc-trial-in-soft-tissue-sarcoma 2025-02-07T23:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-and-philogen-complete-enrollment-for-pivotal-phase-iii-fibrosarc-trial-in-soft-tissue-sarcoma 2025-02-07T23:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/tevogen-bio-presents-exactcell-platform-to-barda-as-potential-rapid-response-viral-countermeasure 2025-02-07T20:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tevogen-bio-presents-exactcell-platform-to-barda-as-potential-rapid-response-viral-countermeasure 2025-02-07T20:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/african-genetic-diversity-opens-new-frontiers-in-global-precision-medicine-research 2025-02-07T17:22:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/african-genetic-diversity-opens-new-frontiers-in-global-precision-medicine-research 2025-02-07T17:22:22+00:00 hourly 0.9 https://trial.medpath.com/news/tnx-1500-shows-promising-safety-profile-in-phase-i-trial-for-transplant-recipients 2025-02-07T16:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tnx-1500-shows-promising-safety-profile-in-phase-i-trial-for-transplant-recipients 2025-02-07T16:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-adar1-inhibitor-rebecsinib-shows-promise-in-halting-cancer-progression-through-space-based-research 2025-02-07T15:34:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-adar1-inhibitor-rebecsinib-shows-promise-in-halting-cancer-progression-through-space-based-research 2025-02-07T15:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-8-7-of-pediatric-patients-lost-medicaid-coverage-during-unwinding-period 2025-02-07T14:00:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-8-7-of-pediatric-patients-lost-medicaid-coverage-during-unwinding-period 2025-02-07T14:00:36+00:00 hourly 0.9 https://trial.medpath.com/news/ct-imaging-predicts-surgical-benefits-of-neoadjuvant-tki-therapy-in-non-metastatic-gist-patients 2025-02-07T13:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ct-imaging-predicts-surgical-benefits-of-neoadjuvant-tki-therapy-in-non-metastatic-gist-patients 2025-02-07T13:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/sclc-incidence-drops-50-over-two-decades-while-survival-rates-remain-stagnant-seer-analysis-shows 2025-02-07T13:21:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sclc-incidence-drops-50-over-two-decades-while-survival-rates-remain-stagnant-seer-analysis-shows 2025-02-07T13:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/fasting-plasma-glucose-emerges-as-key-predictor-in-10-year-diabetes-risk-assessment-study 2025-02-07T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fasting-plasma-glucose-emerges-as-key-predictor-in-10-year-diabetes-risk-assessment-study 2025-02-07T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/replicate-bioscience-s-novel-srrna-rabies-vaccine-shows-promise-in-first-human-trial 2025-02-07T12:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/replicate-bioscience-s-novel-srrna-rabies-vaccine-shows-promise-in-first-human-trial 2025-02-07T12:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/electronic-symptom-monitoring-system-reduces-emergency-visits-and-improves-quality-of-life-in-cancer-patients 2025-02-07T11:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/electronic-symptom-monitoring-system-reduces-emergency-visits-and-improves-quality-of-life-in-cancer-patients 2025-02-07T11:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/ultrasensitive-dna-detection-shows-promise-in-b-cell-lymphoma-remission-assessment 2025-02-07T11:01:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultrasensitive-dna-detection-shows-promise-in-b-cell-lymphoma-remission-assessment 2025-02-07T11:01:51+00:00 hourly 0.9 https://trial.medpath.com/news/turnstone-biologics-discontinues-tidal-01-development-program-for-solid-tumors-despite-early-promise 2025-02-07T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/turnstone-biologics-discontinues-tidal-01-development-program-for-solid-tumors-despite-early-promise 2025-02-07T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gazyva-shows-significant-improvement-in-lupus-nephritis-treatment-phase-iii-regency-trial-results 2025-02-07T10:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gazyva-shows-significant-improvement-in-lupus-nephritis-treatment-phase-iii-regency-trial-results 2025-02-07T10:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-higher-emergency-admissions-and-longer-hospital-stays-for-cancer-patients-with-dementia 2025-02-07T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-higher-emergency-admissions-and-longer-hospital-stays-for-cancer-patients-with-dementia 2025-02-07T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bluewind-medical-s-revi-r-system-shows-sustained-efficacy-for-urinary-incontinence-at-two-year-mark 2025-02-07T09:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bluewind-medical-s-revi-r-system-shows-sustained-efficacy-for-urinary-incontinence-at-two-year-mark 2025-02-07T09:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/surgical-treatment-for-keratinocyte-skin-cancer-proves-safe-in-octogenarians-swiss-study-shows 2025-02-07T09:17:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surgical-treatment-for-keratinocyte-skin-cancer-proves-safe-in-octogenarians-swiss-study-shows 2025-02-07T09:17:39+00:00 hourly 0.9 https://trial.medpath.com/news/mobile-eye-clinic-innovation-streamlines-phase-1-trial-safety-assessments 2025-02-07T08:34:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mobile-eye-clinic-innovation-streamlines-phase-1-trial-safety-assessments 2025-02-07T08:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/tht-2025-groundbreaking-heart-failure-clinical-trials-to-be-presented-at-crf-conference 2025-02-07T08:34:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tht-2025-groundbreaking-heart-failure-clinical-trials-to-be-presented-at-crf-conference 2025-02-07T08:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-to-brensocatib-for-non-cystic-fibrosis-bronchiectasis-treatment 2025-02-07T08:33:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-brensocatib-for-non-cystic-fibrosis-bronchiectasis-treatment 2025-02-07T08:33:45+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-bydureon-fails-to-slow-parkinson-s-disease-progression-in-phase-iii-trial 2025-02-07T08:33:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-bydureon-fails-to-slow-parkinson-s-disease-progression-in-phase-iii-trial 2025-02-07T08:33:22+00:00 hourly 0.9 https://trial.medpath.com/news/cero-therapeutics-secures-5m-funding-advances-novel-cer-t-cell-therapy-towards-phase-1-trial 2025-02-07T08:32:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cero-therapeutics-secures-5m-funding-advances-novel-cer-t-cell-therapy-towards-phase-1-trial 2025-02-07T08:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/major-icu-trial-tests-high-protein-enteral-formula-in-critical-care-patients-across-australia-and-new-zealand 2025-02-07T08:32:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-icu-trial-tests-high-protein-enteral-formula-in-critical-care-patients-across-australia-and-new-zealand 2025-02-07T08:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/vaxcyte-advances-31-valent-pneumococcal-vaccine-to-final-phase-ii-stage-in-infant-trial 2025-02-07T08:32:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaxcyte-advances-31-valent-pneumococcal-vaccine-to-final-phase-ii-stage-in-infant-trial 2025-02-07T08:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-s-ai-discovered-drug-shows-promise-in-phase-ii-brain-disease-trial 2025-02-07T08:31:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-s-ai-discovered-drug-shows-promise-in-phase-ii-brain-disease-trial 2025-02-07T08:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/venovalve-shows-sustained-benefits-in-two-year-follow-up-data-from-u-s-pivotal-trial 2025-02-07T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/venovalve-shows-sustained-benefits-in-two-year-follow-up-data-from-u-s-pivotal-trial 2025-02-07T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/primary-care-practices-show-mixed-evolution-post-covid-enhanced-capabilities-but-reduced-access 2025-02-07T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/primary-care-practices-show-mixed-evolution-post-covid-enhanced-capabilities-but-reduced-access 2025-02-07T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-t-cell-therapy-trial-aims-to-reduce-post-transplant-relapse-in-blood-cancer-patients 2025-02-07T07:57:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-t-cell-therapy-trial-aims-to-reduce-post-transplant-relapse-in-blood-cancer-patients 2025-02-07T07:57:52+00:00 hourly 0.9 https://trial.medpath.com/news/aim-immunotech-advances-ampligen-study-as-potential-avian-flu-vaccine-booster-with-promising-cross-protection 2025-02-07T07:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aim-immunotech-advances-ampligen-study-as-potential-avian-flu-vaccine-booster-with-promising-cross-protection 2025-02-07T07:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-multiple-myeloma-survivors-show-better-outcomes-in-landmark-us-registry-analysis 2025-02-07T07:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-multiple-myeloma-survivors-show-better-outcomes-in-landmark-us-registry-analysis 2025-02-07T07:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-extends-review-period-for-eton-pharmaceuticals-rare-disease-drug-et-400 2025-02-07T06:48:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-extends-review-period-for-eton-pharmaceuticals-rare-disease-drug-et-400 2025-02-07T06:48:58+00:00 hourly 0.9 https://trial.medpath.com/news/novel-non-hormonal-hair-loss-treatment-vdphl01-enters-phase-2-3-clinical-trials 2025-02-07T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-non-hormonal-hair-loss-treatment-vdphl01-enters-phase-2-3-clinical-trials 2025-02-07T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-links-pro-inflammatory-diet-to-higher-youth-hypertension-risk-in-nhanes-analysis 2025-02-07T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-links-pro-inflammatory-diet-to-higher-youth-hypertension-risk-in-nhanes-analysis 2025-02-07T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-study-confirms-safety-of-car-t-cell-therapy-no-link-to-secondary-cancers-found 2025-02-07T04:53:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-study-confirms-safety-of-car-t-cell-therapy-no-link-to-secondary-cancers-found 2025-02-07T04:53:05+00:00 hourly 0.9 https://trial.medpath.com/news/renovorx-secures-12-1m-through-public-offering-to-advance-pancreatic-cancer-trial 2025-02-07T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renovorx-secures-12-1m-through-public-offering-to-advance-pancreatic-cancer-trial 2025-02-07T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bain-capital-acquires-mitsubishi-tanabe-pharma-in-3-3-billion-deal 2025-02-07T02:52:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bain-capital-acquires-mitsubishi-tanabe-pharma-in-3-3-billion-deal 2025-02-07T02:52:18+00:00 hourly 0.9 https://trial.medpath.com/news/healthcare-professionals-express-optimism-for-ai-s-role-in-pharmaceutical-innovation-call-for-ethical-implementation 2025-02-07T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/healthcare-professionals-express-optimism-for-ai-s-role-in-pharmaceutical-innovation-call-for-ethical-implementation 2025-02-07T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alumis-and-acelyrin-announce-merger-to-create-737m-clinical-stage-biopharma-company 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alumis-and-acelyrin-announce-merger-to-create-737m-clinical-stage-biopharma-company 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-confirms-tafinlar-mekinist-combination-s-efficacy-across-age-groups-in-glioma-treatment 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meta-analysis-confirms-tafinlar-mekinist-combination-s-efficacy-across-age-groups-in-glioma-treatment 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/johns-hopkins-cidid-pioneers-next-generation-of-rapid-diagnostic-tests-for-global-health-impact 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johns-hopkins-cidid-pioneers-next-generation-of-rapid-diagnostic-tests-for-global-health-impact 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-biogen-s-vumerity-for-relapsing-remitting-multiple-sclerosis-with-improved-tolerability-profile 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-approves-biogen-s-vumerity-for-relapsing-remitting-multiple-sclerosis-with-improved-tolerability-profile 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-trial-launches-to-develop-personalized-treatments-for-glioblastoma-patients 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-trial-launches-to-develop-personalized-treatments-for-glioblastoma-patients 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tagrisso-shows-higher-cardiac-risk-in-egfr-mutant-lung-cancer-patients-study-reveals 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tagrisso-shows-higher-cardiac-risk-in-egfr-mutant-lung-cancer-patients-study-reveals 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-requests-additional-phase-3-trial-for-santhera-s-dmd-drug-raxone-delaying-approval 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-requests-additional-phase-3-trial-for-santhera-s-dmd-drug-raxone-delaying-approval 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nuance-pharma-s-ohtuvayre-receives-first-approval-outside-us-for-copd-treatment-in-macau 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuance-pharma-s-ohtuvayre-receives-first-approval-outside-us-for-copd-treatment-in-macau 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/protara-therapeutics-reports-72-complete-response-rate-in-nmibc-trial-secures-100m-funding 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protara-therapeutics-reports-72-complete-response-rate-in-nmibc-trial-secures-100m-funding 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/platinum-chemotherapy-shortage-shows-no-impact-on-short-term-mortality-in-advanced-cancer-patients 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/platinum-chemotherapy-shortage-shows-no-impact-on-short-term-mortality-in-advanced-cancer-patients 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dupilumab-shows-limited-success-in-peanut-allergy-desensitization-study 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dupilumab-shows-limited-success-in-peanut-allergy-desensitization-study 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gastrointestinal-organoids-advance-colorectal-cancer-research-through-enhanced-disease-modeling-and-drug-screening 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gastrointestinal-organoids-advance-colorectal-cancer-research-through-enhanced-disease-modeling-and-drug-screening 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/flatiron-health-and-exact-sciences-launch-major-study-to-validate-novel-cancer-recurrence-test 2025-02-06T23:51:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flatiron-health-and-exact-sciences-launch-major-study-to-validate-novel-cancer-recurrence-test 2025-02-06T23:51:25+00:00 hourly 0.9 https://trial.medpath.com/news/genmab-expands-antibody-pipeline-following-profoundbio-deal-plans-further-acquisitions 2025-02-06T23:44:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genmab-expands-antibody-pipeline-following-profoundbio-deal-plans-further-acquisitions 2025-02-06T23:44:44+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-reports-robust-21-revenue-growth-in-2024-projects-strong-pipeline-momentum-for-2025 2025-02-06T22:31:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-reports-robust-21-revenue-growth-in-2024-projects-strong-pipeline-momentum-for-2025 2025-02-06T22:31:20+00:00 hourly 0.9 https://trial.medpath.com/news/washu-s-novel-nasal-covid-19-vaccine-advances-to-u-s-phase-1-clinical-trials 2025-02-06T22:01:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/washu-s-novel-nasal-covid-19-vaccine-advances-to-u-s-phase-1-clinical-trials 2025-02-06T22:01:23+00:00 hourly 0.9 https://trial.medpath.com/news/serina-therapeutics-secures-10m-for-novel-parkinson-s-drug-delivery-system-trial 2025-02-06T21:29:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/serina-therapeutics-secures-10m-for-novel-parkinson-s-drug-delivery-system-trial 2025-02-06T21:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/senseonics-seeks-ce-mark-for-revolutionary-one-year-implantable-glucose-monitor 2025-02-06T21:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senseonics-seeks-ce-mark-for-revolutionary-one-year-implantable-glucose-monitor 2025-02-06T21:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rmat-designation-to-gradalis-personalized-immunotherapy-for-advanced-ovarian-cancer 2025-02-06T21:01:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-rmat-designation-to-gradalis-personalized-immunotherapy-for-advanced-ovarian-cancer 2025-02-06T21:01:24+00:00 hourly 0.9 https://trial.medpath.com/news/aim-vaccine-s-mrna-rsv-vaccine-advances-to-u-s-clinical-trials-with-promising-preclinical-data 2025-02-06T21:01:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aim-vaccine-s-mrna-rsv-vaccine-advances-to-u-s-clinical-trials-with-promising-preclinical-data 2025-02-06T21:01:05+00:00 hourly 0.9 https://trial.medpath.com/news/brain-stimulation-shows-no-added-benefit-for-post-stroke-motor-recovery-in-phase-2-transport-2-trial 2025-02-06T20:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-stimulation-shows-no-added-benefit-for-post-stroke-motor-recovery-in-phase-2-transport-2-trial 2025-02-06T20:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/akeso-completes-enrollment-for-phase-iii-trial-of-ivonescimab-in-squamous-nsclc 2025-02-06T20:01:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akeso-completes-enrollment-for-phase-iii-trial-of-ivonescimab-in-squamous-nsclc 2025-02-06T20:01:02+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-estimabl2-trial-thyroidectomy-without-radioiodine-shows-noninferiority-in-low-risk-thyroid-cancer 2025-02-06T19:10:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-estimabl2-trial-thyroidectomy-without-radioiodine-shows-noninferiority-in-low-risk-thyroid-cancer 2025-02-06T19:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-vaccine-shows-promise-in-advanced-kidney-cancer-trial-with-100-response-rate 2025-02-06T19:01:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-vaccine-shows-promise-in-advanced-kidney-cancer-trial-with-100-response-rate 2025-02-06T19:01:02+00:00 hourly 0.9 https://trial.medpath.com/news/novavax-pursues-full-fda-licensure-for-covid-19-vaccine-advancing-from-eua-status 2025-02-06T18:47:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novavax-pursues-full-fda-licensure-for-covid-19-vaccine-advancing-from-eua-status 2025-02-06T18:47:20+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-s-rec-994-shows-promise-in-phase-ii-trial-for-cerebral-cavernous-malformations 2025-02-06T17:40:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-s-rec-994-shows-promise-in-phase-ii-trial-for-cerebral-cavernous-malformations 2025-02-06T17:40:21+00:00 hourly 0.9 https://trial.medpath.com/news/sangamo-s-gene-therapy-shows-sustained-benefits-in-fabry-disease-patients-with-improved-kidney-function 2025-02-06T17:38:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sangamo-s-gene-therapy-shows-sustained-benefits-in-fabry-disease-patients-with-improved-kidney-function 2025-02-06T17:38:31+00:00 hourly 0.9 https://trial.medpath.com/news/itolizumab-shows-promising-results-in-phase-2-ulcerative-colitis-trial-matching-adalimumab-efficacy 2025-02-06T17:38:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/itolizumab-shows-promising-results-in-phase-2-ulcerative-colitis-trial-matching-adalimumab-efficacy 2025-02-06T17:38:29+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-stakes-80-billion-revenue-goal-on-critical-phase-iii-trial-results-in-2024 2025-02-06T16:52:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-stakes-80-billion-revenue-goal-on-critical-phase-iii-trial-results-in-2024 2025-02-06T16:52:49+00:00 hourly 0.9 https://trial.medpath.com/news/cirm-awards-5-69m-grant-to-advance-novel-gene-therapy-for-spinocerebellar-ataxia-type-3 2025-02-06T16:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cirm-awards-5-69m-grant-to-advance-novel-gene-therapy-for-spinocerebellar-ataxia-type-3 2025-02-06T16:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/shenzhen-zhongge-biotech-advances-development-of-novel-ptpn2-inhibitors 2025-02-06T16:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shenzhen-zhongge-biotech-advances-development-of-novel-ptpn2-inhibitors 2025-02-06T16:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/opdivo-chemotherapy-combination-shows-promise-for-elderly-hodgkin-lymphoma-patients 2025-02-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opdivo-chemotherapy-combination-shows-promise-for-elderly-hodgkin-lymphoma-patients 2025-02-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/kerala-health-initiative-screens-over-1-crore-people-in-major-lifestyle-disease-prevention-drive 2025-02-06T15:46:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kerala-health-initiative-screens-over-1-crore-people-in-major-lifestyle-disease-prevention-drive 2025-02-06T15:46:10+00:00 hourly 0.9 https://trial.medpath.com/news/kura-oncology-s-menin-inhibitor-ziftomenib-shows-promise-in-mid-stage-cancer-trial 2025-02-06T15:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kura-oncology-s-menin-inhibitor-ziftomenib-shows-promise-in-mid-stage-cancer-trial 2025-02-06T15:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-discontinues-two-alexion-rare-disease-programs-amid-strong-q4-performance 2025-02-06T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-discontinues-two-alexion-rare-disease-programs-amid-strong-q4-performance 2025-02-06T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/leronlimab-shows-promising-results-in-reversing-liver-fibrosis-cytodyn-reports 2025-02-06T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leronlimab-shows-promising-results-in-reversing-liver-fibrosis-cytodyn-reports 2025-02-06T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/racial-disparities-found-in-pediatric-migraine-diagnosis-and-treatment-across-us-children-s-hospitals 2025-02-06T13:19:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/racial-disparities-found-in-pediatric-migraine-diagnosis-and-treatment-across-us-children-s-hospitals 2025-02-06T13:19:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-status-to-bracco-s-br55-ultrasound-agent-for-crohn-s-disease-monitoring 2025-02-06T13:11:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-status-to-bracco-s-br55-ultrasound-agent-for-crohn-s-disease-monitoring 2025-02-06T13:11:47+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-trial-for-post-glp-1-weight-management-drug-rdx-002-completes-enrollment-early 2025-02-06T13:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-2-trial-for-post-glp-1-weight-management-drug-rdx-002-completes-enrollment-early 2025-02-06T13:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-expanded-access-program-for-lipella-s-lp-310-in-oral-lichen-planus-treatment 2025-02-06T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-expanded-access-program-for-lipella-s-lp-310-in-oral-lichen-planus-treatment 2025-02-06T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ziftomenib-achieves-primary-endpoint-in-pivotal-aml-trial-kura-and-kyowa-kirin-prepare-fda-filing 2025-02-06T12:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ziftomenib-achieves-primary-endpoint-in-pivotal-aml-trial-kura-and-kyowa-kirin-prepare-fda-filing 2025-02-06T12:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-ide-approval-for-newronika-s-novel-adaptive-deep-brain-stimulation-system-for-parkinson-s-disease 2025-02-06T12:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-ide-approval-for-newronika-s-novel-adaptive-deep-brain-stimulation-system-for-parkinson-s-disease 2025-02-06T12:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/northwestern-medicine-selected-as-first-site-for-pivotal-clarity-trial-testing-nociscan-s-low-back-pain-technology 2025-02-06T12:25:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwestern-medicine-selected-as-first-site-for-pivotal-clarity-trial-testing-nociscan-s-low-back-pain-technology 2025-02-06T12:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/immuneering-partners-with-regeneron-to-test-novel-cancer-drug-combination-for-advanced-lung-cancer 2025-02-06T12:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuneering-partners-with-regeneron-to-test-novel-cancer-drug-combination-for-advanced-lung-cancer 2025-02-06T12:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/protacs-breakthrough-drug-technology-faces-development-hurdles-in-targeting-undruggable-proteins 2025-02-06T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protacs-breakthrough-drug-technology-faces-development-hurdles-in-targeting-undruggable-proteins 2025-02-06T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/recent-clinical-trials-show-promise-of-ketamine-for-rapid-reduction-of-suicidal-ideation 2025-02-06T11:53:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recent-clinical-trials-show-promise-of-ketamine-for-rapid-reduction-of-suicidal-ideation 2025-02-06T11:53:52+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-delays-cagrisema-obesity-drug-filing-to-early-2026 2025-02-06T09:54:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-delays-cagrisema-obesity-drug-filing-to-early-2026 2025-02-06T09:54:02+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-cell-and-gene-therapy-bioanalytical-testing-market-to-reach-349-million-by-2034 2025-02-06T09:27:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-cell-and-gene-therapy-bioanalytical-testing-market-to-reach-349-million-by-2034 2025-02-06T09:27:55+00:00 hourly 0.9 https://trial.medpath.com/news/expres2ion-biotech-advances-to-clinical-phase-with-her2-breast-cancer-vaccine-reports-strong-q4-2024-progress 2025-02-06T09:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expres2ion-biotech-advances-to-clinical-phase-with-her2-breast-cancer-vaccine-reports-strong-q4-2024-progress 2025-02-06T09:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/gallup-emory-survey-healthcare-access-and-costs-top-americans-public-health-priorities 2025-02-06T08:22:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gallup-emory-survey-healthcare-access-and-costs-top-americans-public-health-priorities 2025-02-06T08:22:34+00:00 hourly 0.9 https://trial.medpath.com/news/vaxxas-strengthens-development-team-with-global-vaccine-experts-ahead-of-late-stage-trials 2025-02-06T07:38:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaxxas-strengthens-development-team-with-global-vaccine-experts-ahead-of-late-stage-trials 2025-02-06T07:38:40+00:00 hourly 0.9 https://trial.medpath.com/news/ai-chatbot-matches-standard-care-in-facilitating-cancer-genetic-testing-access-bridge-trial-shows 2025-02-06T07:00:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-chatbot-matches-standard-care-in-facilitating-cancer-genetic-testing-access-bridge-trial-shows 2025-02-06T07:00:11+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-to-present-extensive-immunology-data-at-aaaai-2025-highlighting-dupixent-and-pipeline-advances 2025-02-06T06:05:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-to-present-extensive-immunology-data-at-aaaai-2025-highlighting-dupixent-and-pipeline-advances 2025-02-06T06:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/sacituzumab-govitecan-shows-promise-in-treating-brain-metastases-and-glioblastoma-in-phase-0-trial 2025-02-06T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sacituzumab-govitecan-shows-promise-in-treating-brain-metastases-and-glioblastoma-in-phase-0-trial 2025-02-06T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/daybue-clinical-trials-show-significant-communication-and-motor-improvements-in-rett-syndrome-patients 2025-02-06T05:58:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daybue-clinical-trials-show-significant-communication-and-motor-improvements-in-rett-syndrome-patients 2025-02-06T05:58:59+00:00 hourly 0.9 https://trial.medpath.com/news/novavax-s-xbb-1-5-based-covid-19-booster-shows-superior-immune-response-in-phase-2-3-trial 2025-02-06T05:09:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novavax-s-xbb-1-5-based-covid-19-booster-shows-superior-immune-response-in-phase-2-3-trial 2025-02-06T05:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-requires-additional-efficacy-study-for-lipocine-s-oral-postpartum-depression-treatment-lpcn-1154 2025-02-06T04:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-requires-additional-efficacy-study-for-lipocine-s-oral-postpartum-depression-treatment-lpcn-1154 2025-02-06T04:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-announces-2-billion-cost-cutting-plan-amid-patent-cliff-challenges 2025-02-06T04:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-announces-2-billion-cost-cutting-plan-amid-patent-cliff-challenges 2025-02-06T04:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-reports-doubled-q4-profits-driven-by-surging-obesity-and-diabetes-drug-sales 2025-02-06T03:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-reports-doubled-q4-profits-driven-by-surging-obesity-and-diabetes-drug-sales 2025-02-06T03:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/caris-life-sciences-to-present-novel-cancer-research-at-2025-asco-gu-symposium 2025-02-06T03:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caris-life-sciences-to-present-novel-cancer-research-at-2025-asco-gu-symposium 2025-02-06T03:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/next-generation-antibody-drug-discovery-merging-ai-and-functional-screening-to-unlock-novel-therapeutics 2025-02-06T02:53:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-generation-antibody-drug-discovery-merging-ai-and-functional-screening-to-unlock-novel-therapeutics 2025-02-06T02:53:34+00:00 hourly 0.9 https://trial.medpath.com/news/psm-challenges-hims-hers-super-bowl-ad-for-compounded-semaglutide 2025-02-06T02:27:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psm-challenges-hims-hers-super-bowl-ad-for-compounded-semaglutide 2025-02-06T02:27:19+00:00 hourly 0.9 https://trial.medpath.com/news/spago-nanomedical-advances-tumorad-program-streamlines-operations-for-clinical-development-focus 2025-02-06T02:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spago-nanomedical-advances-tumorad-program-streamlines-operations-for-clinical-development-focus 2025-02-06T02:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/qlaris-reports-positive-phase-ii-results-for-qls-111-in-reducing-intraocular-pressure 2025-02-06T01:54:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qlaris-reports-positive-phase-ii-results-for-qls-111-in-reducing-intraocular-pressure 2025-02-06T01:54:01+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-s-rec-994-shows-promising-safety-and-efficacy-signals-in-phase-2-ccm-trial 2025-02-06T01:24:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-s-rec-994-shows-promising-safety-and-efficacy-signals-in-phase-2-ccm-trial 2025-02-06T01:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/belite-bio-secures-15-million-in-direct-offering-to-advance-retinal-disease-therapeutics 2025-02-06T01:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belite-bio-secures-15-million-in-direct-offering-to-advance-retinal-disease-therapeutics 2025-02-06T01:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/belite-bio-secures-15-million-through-direct-offering-to-advance-tinlarebant-development 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belite-bio-secures-15-million-through-direct-offering-to-advance-tinlarebant-development 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bioxcel-therapeutics-advances-phase-3-trials-for-bxcl501-in-agitation-treatment 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioxcel-therapeutics-advances-phase-3-trials-for-bxcl501-in-agitation-treatment 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-and-roche-seek-fda-approval-for-venclexta-gazyva-combination-in-first-line-cll-treatment 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-and-roche-seek-fda-approval-for-venclexta-gazyva-combination-in-first-line-cll-treatment 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-walk-n-watch-protocol-shows-significant-improvements-in-post-stroke-recovery 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-walk-n-watch-protocol-shows-significant-improvements-in-post-stroke-recovery 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/enlivex-reports-promising-results-in-phase-i-ii-trial-of-allocetra-for-severe-knee-osteoarthritis 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enlivex-reports-promising-results-in-phase-i-ii-trial-of-allocetra-for-severe-knee-osteoarthritis 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/qureight-s-ai-imaging-platform-to-support-avalyn-s-inhaled-pirfenidone-trial-in-pulmonary-fibrosis 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qureight-s-ai-imaging-platform-to-support-avalyn-s-inhaled-pirfenidone-trial-in-pulmonary-fibrosis 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mrd-guided-ibrutinib-venetoclax-therapy-shows-superior-outcomes-in-cll-treatment-flair-trial-results 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrd-guided-ibrutinib-venetoclax-therapy-shows-superior-outcomes-in-cll-treatment-flair-trial-results 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-appoints-former-novartis-executive-jeffrey-legos-as-chief-oncology-officer-to-strengthen-cancer-drug-portfolio 2025-02-05T23:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-appoints-former-novartis-executive-jeffrey-legos-as-chief-oncology-officer-to-strengthen-cancer-drug-portfolio 2025-02-05T23:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/hbm-holdings-secures-nmpa-approval-to-begin-copd-drug-trials-in-china 2025-02-05T23:31:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hbm-holdings-secures-nmpa-approval-to-begin-copd-drug-trials-in-china 2025-02-05T23:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/jupiter-neurosciences-advances-jotrol-platform-with-phase-2a-parkinson-s-trial-and-consumer-product-launch 2025-02-05T23:31:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jupiter-neurosciences-advances-jotrol-platform-with-phase-2a-parkinson-s-trial-and-consumer-product-launch 2025-02-05T23:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-trial-shows-glp-1-drug-exenatide-ineffective-for-parkinson-s-disease-treatment 2025-02-05T23:01:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-trial-shows-glp-1-drug-exenatide-ineffective-for-parkinson-s-disease-treatment 2025-02-05T23:01:49+00:00 hourly 0.9 https://trial.medpath.com/news/blinklab-launches-fda-registrational-trial-for-ai-powered-autism-diagnostic-tool 2025-02-05T23:01:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blinklab-launches-fda-registrational-trial-for-ai-powered-autism-diagnostic-tool 2025-02-05T23:01:32+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-launches-ps11m-ai-powered-breast-cancer-screening-trial-involving-700000-women 2025-02-05T23:01:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-launches-ps11m-ai-powered-breast-cancer-screening-trial-involving-700000-women 2025-02-05T23:01:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-cellular-enabled-sansa-home-sleep-apnea-test-eliminating-need-for-smartphone-apps 2025-02-05T22:30:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-cellular-enabled-sansa-home-sleep-apnea-test-eliminating-need-for-smartphone-apps 2025-02-05T22:30:38+00:00 hourly 0.9 https://trial.medpath.com/news/tinivo-2-trial-shows-no-added-benefit-of-nivolumab-combination-in-io-refractory-rcc-treatment 2025-02-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tinivo-2-trial-shows-no-added-benefit-of-nivolumab-combination-in-io-refractory-rcc-treatment 2025-02-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/identiv-and-novanta-partner-to-advance-rfid-technology-in-medical-devices-and-pharmaceuticals 2025-02-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/identiv-and-novanta-partner-to-advance-rfid-technology-in-medical-devices-and-pharmaceuticals 2025-02-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/respiratory-function-monitoring-improves-supraglottic-airway-device-placement-in-neonates-study-shows 2025-02-05T21:57:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/respiratory-function-monitoring-improves-supraglottic-airway-device-placement-in-neonates-study-shows 2025-02-05T21:57:46+00:00 hourly 0.9 https://trial.medpath.com/news/duravyu-shows-promising-results-in-phase-2-verona-trial-for-retinal-diseases 2025-02-05T20:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duravyu-shows-promising-results-in-phase-2-verona-trial-for-retinal-diseases 2025-02-05T20:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-status-to-acrivon-s-ai-powered-cancer-diagnostic-platform 2025-02-05T20:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-status-to-acrivon-s-ai-powered-cancer-diagnostic-platform 2025-02-05T20:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/usc-secures-10-8m-pcori-grant-to-compare-hip-fracture-surgery-approaches-in-elderly-patients 2025-02-05T20:55:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usc-secures-10-8m-pcori-grant-to-compare-hip-fracture-surgery-approaches-in-elderly-patients 2025-02-05T20:55:54+00:00 hourly 0.9 https://trial.medpath.com/news/glucotrack-s-novel-implantable-blood-glucose-monitor-shows-promise-in-first-human-trial 2025-02-05T20:01:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glucotrack-s-novel-implantable-blood-glucose-monitor-shows-promise-in-first-human-trial 2025-02-05T20:01:05+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-neoantigen-vaccine-shows-promise-in-renal-cell-carcinoma-clinical-trial 2025-02-05T19:37:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-neoantigen-vaccine-shows-promise-in-renal-cell-carcinoma-clinical-trial 2025-02-05T19:37:19+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-reinforces-strict-controls-on-ketamine-nasal-spray-for-depression-treatment 2025-02-05T18:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-reinforces-strict-controls-on-ketamine-nasal-spray-for-depression-treatment 2025-02-05T18:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/blinklab-advances-smartphone-based-autism-diagnostic-tool-with-first-u-s-clinical-trial-site 2025-02-05T18:44:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blinklab-advances-smartphone-based-autism-diagnostic-tool-with-first-u-s-clinical-trial-site 2025-02-05T18:44:58+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-abu-dhabi-pioneers-first-gcc-breast-cancer-recurrence-trial-with-astrazeneca 2025-02-05T18:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleveland-clinic-abu-dhabi-pioneers-first-gcc-breast-cancer-recurrence-trial-with-astrazeneca 2025-02-05T18:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/miist-therapeutics-secures-7m-seed-funding-for-ultra-rapid-inhaled-drug-delivery-platform 2025-02-05T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/miist-therapeutics-secures-7m-seed-funding-for-ultra-rapid-inhaled-drug-delivery-platform 2025-02-05T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-places-amgen-s-obesity-drug-amg-513-trial-on-clinical-hold 2025-02-05T17:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-places-amgen-s-obesity-drug-amg-513-trial-on-clinical-hold 2025-02-05T17:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/macustar-study-validates-novel-endpoints-for-age-related-macular-degeneration-clinical-trials 2025-02-05T16:59:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/macustar-study-validates-novel-endpoints-for-age-related-macular-degeneration-clinical-trials 2025-02-05T16:59:06+00:00 hourly 0.9 https://trial.medpath.com/news/astellas-seeks-first-japanese-approval-for-geographic-atrophy-treatment-with-avacincaptad-pegol 2025-02-05T16:47:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astellas-seeks-first-japanese-approval-for-geographic-atrophy-treatment-with-avacincaptad-pegol 2025-02-05T16:47:31+00:00 hourly 0.9 https://trial.medpath.com/news/nutrition-platform-fay-secures-50m-series-b-funding-amid-glp-1-weight-loss-drug-boom 2025-02-05T16:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nutrition-platform-fay-secures-50m-series-b-funding-amid-glp-1-weight-loss-drug-boom 2025-02-05T16:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-faces-strategic-challenges-as-29-5b-keytruda-patent-cliff-approaches-in-2028 2025-02-05T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-faces-strategic-challenges-as-29-5b-keytruda-patent-cliff-approaches-in-2028 2025-02-05T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-spinal-cord-stimulation-shows-promise-in-treating-spinal-muscular-atrophy 2025-02-05T16:02:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-spinal-cord-stimulation-shows-promise-in-treating-spinal-muscular-atrophy 2025-02-05T16:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-and-health-canada-clear-alys-pharmaceuticals-aly-101-for-phase-iia-alopecia-areata-trial 2025-02-05T15:38:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-and-health-canada-clear-alys-pharmaceuticals-aly-101-for-phase-iia-alopecia-areata-trial 2025-02-05T15:38:21+00:00 hourly 0.9 https://trial.medpath.com/news/eyepoint-s-duravyu-shows-promising-results-in-phase-2-dme-trial-with-extended-treatment-duration 2025-02-05T15:34:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eyepoint-s-duravyu-shows-promising-results-in-phase-2-dme-trial-with-extended-treatment-duration 2025-02-05T15:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/e-star-biotech-initiates-phase-2-trial-of-manp-for-resistant-hypertension-treatment 2025-02-05T15:34:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/e-star-biotech-initiates-phase-2-trial-of-manp-for-resistant-hypertension-treatment 2025-02-05T15:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-expansion-of-decoy20-cancer-immunotherapy-trial 2025-02-05T15:34:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-expansion-of-decoy20-cancer-immunotherapy-trial 2025-02-05T15:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-acrivon-s-acr-368-oncosignature-test-for-endometrial-cancer 2025-02-05T15:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-acrivon-s-acr-368-oncosignature-test-for-endometrial-cancer 2025-02-05T15:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-partnership-launches-revolutionary-mrna-vaccine-platform-to-boost-african-manufacturing-independence 2025-02-05T14:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-partnership-launches-revolutionary-mrna-vaccine-platform-to-boost-african-manufacturing-independence 2025-02-05T14:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/eu-approves-serplulimab-as-first-anti-pd-1-therapy-for-first-line-es-sclc-treatment 2025-02-05T14:32:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-approves-serplulimab-as-first-anti-pd-1-therapy-for-first-line-es-sclc-treatment 2025-02-05T14:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/wandercraft-initiates-landmark-trial-for-hands-free-personal-exoskeleton-in-sci-patients 2025-02-05T14:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wandercraft-initiates-landmark-trial-for-hands-free-personal-exoskeleton-in-sci-patients 2025-02-05T14:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/remote-clinical-pharmacists-drive-5-9m-cost-savings-in-community-oncology-study 2025-02-05T14:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remote-clinical-pharmacists-drive-5-9m-cost-savings-in-community-oncology-study 2025-02-05T14:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-ceo-expresses-confidence-in-medicare-price-negotiations-for-glp-1-drugs 2025-02-05T14:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-ceo-expresses-confidence-in-medicare-price-negotiations-for-glp-1-drugs 2025-02-05T14:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/inspira-technologies-enhances-hyla-blood-sensor-with-ai-powered-oxygenation-monitoring 2025-02-05T13:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inspira-technologies-enhances-hyla-blood-sensor-with-ai-powered-oxygenation-monitoring 2025-02-05T13:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-trial-shows-promise-for-bms-986354-car-t-cell-therapy-in-multiple-myeloma 2025-02-05T13:28:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-trial-shows-promise-for-bms-986354-car-t-cell-therapy-in-multiple-myeloma 2025-02-05T13:28:09+00:00 hourly 0.9 https://trial.medpath.com/news/aim-immunotech-advances-to-phase-2-trial-of-ampligen-imfinzi-combination-for-late-stage-pancreatic-cancer 2025-02-05T13:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aim-immunotech-advances-to-phase-2-trial-of-ampligen-imfinzi-combination-for-late-stage-pancreatic-cancer 2025-02-05T13:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/2-million-grant-awarded-to-advance-gene-therapy-trial-for-rare-childhood-blindness 2025-02-05T13:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/2-million-grant-awarded-to-advance-gene-therapy-trial-for-rare-childhood-blindness 2025-02-05T13:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-baricitinib-as-first-systemic-treatment-for-severe-alopecia-areata-based-on-phase-3-trial-results 2025-02-05T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-baricitinib-as-first-systemic-treatment-for-severe-alopecia-areata-based-on-phase-3-trial-results 2025-02-05T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/city-of-hope-expert-highlights-critical-gaps-in-precision-medicine-implementation-for-cancer-care 2025-02-05T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/city-of-hope-expert-highlights-critical-gaps-in-precision-medicine-implementation-for-cancer-care 2025-02-05T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/medicaid-cgt-access-model-s-future-uncertain-amid-policy-changes 2025-02-05T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicaid-cgt-access-model-s-future-uncertain-amid-policy-changes 2025-02-05T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-supports-phase-iii-development-of-novel-non-invasive-endometriosis-imaging-test 2025-02-05T12:02:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-supports-phase-iii-development-of-novel-non-invasive-endometriosis-imaging-test 2025-02-05T12:02:33+00:00 hourly 0.9 https://trial.medpath.com/news/novel-synthetic-lethal-approaches-show-promise-in-targeting-mtap-and-smarca4-mutations-in-lung-cancer 2025-02-05T12:02:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-synthetic-lethal-approaches-show-promise-in-targeting-mtap-and-smarca4-mutations-in-lung-cancer 2025-02-05T12:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/msd-and-cellbion-partner-to-test-novel-radioligand-immunotherapy-combination-for-advanced-prostate-cancer 2025-02-05T11:25:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/msd-and-cellbion-partner-to-test-novel-radioligand-immunotherapy-combination-for-advanced-prostate-cancer 2025-02-05T11:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-trial-shows-promise-tislelizumab-plus-chemotherapy-demonstrates-strong-results-in-advanced-gastroesophageal-cancer 2025-02-05T11:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-2-trial-shows-promise-tislelizumab-plus-chemotherapy-demonstrates-strong-results-in-advanced-gastroesophageal-cancer 2025-02-05T11:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/low-dose-glucocorticoids-show-no-benefit-for-skin-fibrosis-in-early-systemic-sclerosis-study 2025-02-05T10:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/low-dose-glucocorticoids-show-no-benefit-for-skin-fibrosis-in-early-systemic-sclerosis-study 2025-02-05T10:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/algiax-s-novel-non-opioid-ap-325-shows-promise-in-phase-2a-neuropathic-pain-trial 2025-02-05T10:33:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/algiax-s-novel-non-opioid-ap-325-shows-promise-in-phase-2a-neuropathic-pain-trial 2025-02-05T10:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-backs-durvalumab-for-limited-stage-sclc-following-chemoradiation-success 2025-02-05T10:32:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-backs-durvalumab-for-limited-stage-sclc-following-chemoradiation-success 2025-02-05T10:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-susvimo-for-diabetic-macular-edema-first-continuous-delivery-ranibizumab-treatment 2025-02-05T10:32:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-susvimo-for-diabetic-macular-edema-first-continuous-delivery-ranibizumab-treatment 2025-02-05T10:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-for-wiskott-aldrich-syndrome-under-ema-review 2025-02-05T10:32:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-for-wiskott-aldrich-syndrome-under-ema-review 2025-02-05T10:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/ema-approves-neurotherapia-s-phase-2-trial-for-novel-alzheimer-s-drug-ntrx-07 2025-02-05T10:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-approves-neurotherapia-s-phase-2-trial-for-novel-alzheimer-s-drug-ntrx-07 2025-02-05T10:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/united-therapeutics-completes-enrollment-in-pivotal-teton-1-trial-for-ipf-treatment 2025-02-05T10:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/united-therapeutics-completes-enrollment-in-pivotal-teton-1-trial-for-ipf-treatment 2025-02-05T10:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-raises-2031-revenue-target-to-ps40-billion-despite-zantac-impact-on-profits 2025-02-05T09:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-raises-2031-revenue-target-to-ps40-billion-despite-zantac-impact-on-profits 2025-02-05T09:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/sernova-files-ind-for-novel-bio-hybrid-thyroid-treatment-advancing-cell-pouch-technology-beyond-diabetes 2025-02-05T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sernova-files-ind-for-novel-bio-hybrid-thyroid-treatment-advancing-cell-pouch-technology-beyond-diabetes 2025-02-05T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/turnstone-biologics-halts-tidal-01-development-explores-strategic-alternatives-amid-financial-constraints 2025-02-05T08:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/turnstone-biologics-halts-tidal-01-development-explores-strategic-alternatives-amid-financial-constraints 2025-02-05T08:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/lantheus-to-present-new-pylarify-data-for-early-prostate-cancer-detection-at-asco-gu-2025 2025-02-05T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantheus-to-present-new-pylarify-data-for-early-prostate-cancer-detection-at-asco-gu-2025 2025-02-05T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/european-clinical-trial-supply-conference-2025-to-focus-on-ai-integration-and-supply-chain-innovation 2025-02-05T08:16:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-clinical-trial-supply-conference-2025-to-focus-on-ai-integration-and-supply-chain-innovation 2025-02-05T08:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-raises-five-year-revenue-target-to-ps40bn-following-strong-specialty-medicines-growth 2025-02-05T07:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-raises-five-year-revenue-target-to-ps40bn-following-strong-specialty-medicines-growth 2025-02-05T07:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/viking-therapeutics-advances-novel-oral-glp-1-gip-dual-agonist-vk2735-to-phase-2-trial-for-obesity-treatment 2025-02-05T07:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viking-therapeutics-advances-novel-oral-glp-1-gip-dual-agonist-vk2735-to-phase-2-trial-for-obesity-treatment 2025-02-05T07:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-bnct-cancer-treatment-breakthrough-neuboron-medical-group-reports-success-with-first-domestic-system 2025-02-05T07:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-bnct-cancer-treatment-breakthrough-neuboron-medical-group-reports-success-with-first-domestic-system 2025-02-05T07:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-cldn6-targeted-therapies-show-promise-in-advanced-solid-tumors 2025-02-05T06:00:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-cldn6-targeted-therapies-show-promise-in-advanced-solid-tumors 2025-02-05T06:00:02+00:00 hourly 0.9 https://trial.medpath.com/news/global-survey-reveals-critical-knowledge-gaps-in-genetic-testing-for-ovarian-cancer-treatment 2025-02-05T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-survey-reveals-critical-knowledge-gaps-in-genetic-testing-for-ovarian-cancer-treatment 2025-02-05T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-raises-2031-sales-target-to-ps40-billion-driven-by-strong-pipeline-progress 2025-02-05T05:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-raises-2031-sales-target-to-ps40-billion-driven-by-strong-pipeline-progress 2025-02-05T05:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/diagnos-secures-2-million-in-private-placement-to-advance-ai-based-healthcare-screening-technology 2025-02-05T05:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diagnos-secures-2-million-in-private-placement-to-advance-ai-based-healthcare-screening-technology 2025-02-05T05:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/lnp-mrna-technology-evolution-and-bioanalytical-advances-reshape-drug-delivery-landscape 2025-02-05T05:13:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lnp-mrna-technology-evolution-and-bioanalytical-advances-reshape-drug-delivery-landscape 2025-02-05T05:13:40+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-portfolio-resilience-cancer-and-hiv-gains-offset-rsv-vaccine-decline 2025-02-05T04:50:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-portfolio-resilience-cancer-and-hiv-gains-offset-rsv-vaccine-decline 2025-02-05T04:50:15+00:00 hourly 0.9 https://trial.medpath.com/news/delveinsight-report-over-50-pipeline-drugs-in-development-for-urothelial-carcinoma-treatment 2025-02-05T04:10:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delveinsight-report-over-50-pipeline-drugs-in-development-for-urothelial-carcinoma-treatment 2025-02-05T04:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/jabil-expands-pharmaceutical-manufacturing-capabilities-with-strategic-pii-acquisition 2025-02-05T01:41:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jabil-expands-pharmaceutical-manufacturing-capabilities-with-strategic-pii-acquisition 2025-02-05T01:41:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-greenlights-clinical-trials-for-pig-to-human-kidney-transplants 2025-02-05T00:43:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-greenlights-clinical-trials-for-pig-to-human-kidney-transplants 2025-02-05T00:43:04+00:00 hourly 0.9 https://trial.medpath.com/news/pathmaker-s-myoregulator-device-for-als-treatment-receives-irb-approval-for-dod-funded-clinical-trial 2025-02-05T00:01:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pathmaker-s-myoregulator-device-for-als-treatment-receives-irb-approval-for-dod-funded-clinical-trial 2025-02-05T00:01:43+00:00 hourly 0.9 https://trial.medpath.com/news/divergent-clinical-evidence-submissions-revealed-in-fda-and-ema-cell-and-gene-therapy-approvals 2025-02-05T00:01:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/divergent-clinical-evidence-submissions-revealed-in-fda-and-ema-cell-and-gene-therapy-approvals 2025-02-05T00:01:26+00:00 hourly 0.9 https://trial.medpath.com/news/alzheon-to-present-phase-3-data-for-novel-apoe4-targeted-alzheimer-s-pill-in-april-2025 2025-02-05T00:01:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzheon-to-present-phase-3-data-for-novel-apoe4-targeted-alzheimer-s-pill-in-april-2025 2025-02-05T00:01:01+00:00 hourly 0.9 https://trial.medpath.com/news/ai-assisted-physicians-show-enhanced-clinical-decision-making-in-landmark-study 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-assisted-physicians-show-enhanced-clinical-decision-making-in-landmark-study 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/priority-health-enhances-healthcare-navigation-platform-with-extended-support-services 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/priority-health-enhances-healthcare-navigation-platform-with-extended-support-services 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/libtayo-becomes-first-eu-approved-immunotherapy-for-advanced-cervical-cancer 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/libtayo-becomes-first-eu-approved-immunotherapy-for-advanced-cervical-cancer 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-evolocumab-shows-strong-benefits-for-elderly-ascvd-patients-in-fourier-trial-analysis 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-evolocumab-shows-strong-benefits-for-elderly-ascvd-patients-in-fourier-trial-analysis 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-algorithm-successfully-predicts-cancer-outcomes-using-clinical-notes-analysis 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-algorithm-successfully-predicts-cancer-outcomes-using-clinical-notes-analysis 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-withdraws-aduhelm-eu-application-following-regulatory-setback 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-withdraws-aduhelm-eu-application-following-regulatory-setback 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iib-adagio-trial-adavosertib-shows-limited-efficacy-with-high-toxicity-in-uterine-serous-carcinoma 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iib-adagio-trial-adavosertib-shows-limited-efficacy-with-high-toxicity-in-uterine-serous-carcinoma 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/groundbreaking-t-cell-therapy-leads-to-complete-remission-in-stage-4-breast-cancer-patient 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/groundbreaking-t-cell-therapy-leads-to-complete-remission-in-stage-4-breast-cancer-patient 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/oct-analysis-reveals-key-predictors-of-visual-recovery-in-macula-off-retinal-detachment 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oct-analysis-reveals-key-predictors-of-visual-recovery-in-macula-off-retinal-detachment 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/quality-of-life-comparable-between-erleada-combinations-in-advanced-prostate-cancer-treatment 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quality-of-life-comparable-between-erleada-combinations-in-advanced-prostate-cancer-treatment 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/coa-unveils-comprehensive-healthcare-reform-plan-to-address-cancer-care-crisis 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coa-unveils-comprehensive-healthcare-reform-plan-to-address-cancer-care-crisis 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alberta-innovates-awards-600k-grant-to-voyageur-pharmaceuticals-for-advanced-barium-contrast-media-research 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alberta-innovates-awards-600k-grant-to-voyageur-pharmaceuticals-for-advanced-barium-contrast-media-research 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astellas-discontinues-dmd-gene-therapy-programs-takes-170m-impairment-charge 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astellas-discontinues-dmd-gene-therapy-programs-takes-170m-impairment-charge 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/formycon-expands-global-reach-for-eylea-biosimilar-through-strategic-partnerships-with-teva-and-lotus-pharmaceutical 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formycon-expands-global-reach-for-eylea-biosimilar-through-strategic-partnerships-with-teva-and-lotus-pharmaceutical 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/major-pipeline-expansion-in-schizophrenia-treatment-55-companies-developing-60-novel-therapies 2025-02-04T23:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pipeline-expansion-in-schizophrenia-treatment-55-companies-developing-60-novel-therapies 2025-02-04T23:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/emyria-reports-significant-mdma-assisted-therapy-benefits-for-ptsd-in-clinical-trial 2025-02-04T23:31:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emyria-reports-significant-mdma-assisted-therapy-benefits-for-ptsd-in-clinical-trial 2025-02-04T23:31:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-places-clinical-hold-on-amgen-s-novel-obesity-drug-candidate-amg-513 2025-02-04T22:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-places-clinical-hold-on-amgen-s-novel-obesity-drug-candidate-amg-513 2025-02-04T22:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reviews-pertuzumab-biosimilar-hlx11-for-her2-positive-breast-cancer-treatment 2025-02-04T22:14:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-reviews-pertuzumab-biosimilar-hlx11-for-her2-positive-breast-cancer-treatment 2025-02-04T22:14:06+00:00 hourly 0.9 https://trial.medpath.com/news/revive-therapeutics-advances-bucillamine-research-for-nerve-agent-exposure-and-long-covid-treatment 2025-02-04T21:31:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revive-therapeutics-advances-bucillamine-research-for-nerve-agent-exposure-and-long-covid-treatment 2025-02-04T21:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-clinical-trials-showcase-growing-promise-of-radiopharmaceutical-cancer-therapy 2025-02-04T21:22:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-clinical-trials-showcase-growing-promise-of-radiopharmaceutical-cancer-therapy 2025-02-04T21:22:37+00:00 hourly 0.9 https://trial.medpath.com/news/nanoscope-to-present-126-week-vision-restoration-data-for-mco-010-gene-therapy-in-retinitis-pigmentosa 2025-02-04T21:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoscope-to-present-126-week-vision-restoration-data-for-mco-010-gene-therapy-in-retinitis-pigmentosa 2025-02-04T21:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/iit-guwahati-pioneers-adaptive-clinical-trial-method-for-personalized-medicine 2025-02-04T20:31:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iit-guwahati-pioneers-adaptive-clinical-trial-method-for-personalized-medicine 2025-02-04T20:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-clinical-trials-for-pig-to-human-kidney-transplants 2025-02-04T20:31:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-clinical-trials-for-pig-to-human-kidney-transplants 2025-02-04T20:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/next-gen-ozempic-combo-drug-cagrisema-shows-22-7-weight-loss-with-mixed-patient-experiences 2025-02-04T20:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-gen-ozempic-combo-drug-cagrisema-shows-22-7-weight-loss-with-mixed-patient-experiences 2025-02-04T20:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/brolucizumab-shows-promising-one-year-results-in-wet-amd-treatment-regardless-of-prior-therapy 2025-02-04T19:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brolucizumab-shows-promising-one-year-results-in-wet-amd-treatment-regardless-of-prior-therapy 2025-02-04T19:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/trilink-and-aldevron-partner-to-expand-access-to-cleancap-r-mrna-technology-for-therapeutic-development 2025-02-04T16:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trilink-and-aldevron-partner-to-expand-access-to-cleancap-r-mrna-technology-for-therapeutic-development 2025-02-04T16:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/zoetis-updates-librela-label-following-reports-of-severe-side-effects-in-dogs 2025-02-04T15:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zoetis-updates-librela-label-following-reports-of-severe-side-effects-in-dogs 2025-02-04T15:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/world-cancer-day-2025-launches-united-by-unique-campaign-as-nccn-patient-advocates-share-personal-journeys 2025-02-04T15:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-cancer-day-2025-launches-united-by-unique-campaign-as-nccn-patient-advocates-share-personal-journeys 2025-02-04T15:33:00+00:00 hourly 0.9